

Review

Not peer-reviewed version

NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development

[Inamul Haque](#)^{*}, [Pritam Thapa](#), Douglas M Burns, Jianping Zhou, [Mukut Sharma](#), Ram Sharma, [Vikas Singh](#)^{*}

Posted Date: 10 May 2024

doi: 10.20944/preprints202405.0668.v1

Keywords: epilepsy; neuroinflammation; NLRP3 inflammasome; epileptogenesis; antiseizure medication; interleukin-1b; caspase-1; ASC



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development

Inamul Haque ^{1,2,3,*}, Pritam Thapa ^{1,4}, Douglas M Burns ¹, Jianping Zhou ⁵, Mukut Sharma ^{1,4,5}, Ram Sharma ¹ and Vikas Singh ^{1,4,6,*}

¹ Research and Development Service, Kansas City Veterans Affairs Medical Center, Kansas City, MO, United States.; pritam.thapa@va.gov (P.T.); dmburns9@yahoo.com (D.M.B.); Mukut.sharma@va.gov (M.S.); ram.sharma2@va.gov (R.S.)

² Department of Math, Science and Business Technology, Kansas City Kansas Community College, Kansas City, Kansas.; ihaque@kumc.edu

³ Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.; ihaque@kckcc.edu

⁴ Drug Discovery Program, Midwest Veterans' Biomedical Research Foundation, KCVA Medical Center, Kansas City, MO 64128, USA

⁵ Renal Research Laboratory, Kansas City VA Medical Center, Kansas City, MO, USA; jianping.zhou@va.gov

⁶ Division of Neurology, KCVA Medical Center, Kansas City, MO, USA

* Correspondence: inamul.haque@va.gov (I.H.); vikas.singh3@va.gov (V.S.)

Abstract: Epilepsy is one of the most prevalent and serious brain disorders, affecting 70 million people worldwide. Antiseizure medications (ASMs) though relieve symptoms and prevent the occurrence of future seizures in epileptic patients have limited effect on epileptogenesis. Addressing the multifaceted nature of epileptogenesis and its association with Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated neuroinflammation requires a comprehensive understanding of the underlying mechanisms for development of targeted therapeutic strategies beyond conventional antiseizure treatments. Several types of NLRP3 inhibitors have been developed and their effect has been validated both in vitro and in vivo models of epileptogenesis. In this review, we discuss the advances in understanding the regulatory mechanisms of NLRP3 activation as well as progress made and challenges facing in the development of NLRP3 inhibitors for the treatment of epilepsy.

Keywords: epilepsy; neuroinflammation; NLRP3 inflammasome; epileptogenesis; antiseizure medication; interleukin-1b; caspase-1; ASC

1. Introduction

Epilepsy is a serious chronic brain disorder characterized by spontaneous and recurrent seizures [1,2] that affects more than 70 million people worldwide [3]. Approximately 3 million adults and 470,000 children suffer from epilepsy with an incidence of about 150,000 new cases each year in the USA [4]. According to the World Health Organization, roughly half of epilepsy cases have no known cause whereas the other half may be due to imbalance of neurotransmitters, brain tumors, strokes, immune disorders, gene mutations, and traumatic brain injury. The majority of epileptic patients also suffer from depression and memory loss resulting in poor quality of life and reduced life expectancy [5]. Use of antiseizure medications (ASMs) remain the preferred treatment and seizures are being effectively controlled in 70% of the epileptic patients [6]. Although more than 30 FDA approved ASMs with diverse molecular targets are available for therapeutic purpose [7], the biggest challenge in the clinical treatment of epilepsy is that about 30% of epileptic patients develop resistance to ASMs. There is an urgent need to develop newer drugs with better efficacy, fewer side effects and less toxicity. This need is further augmented by the fact that available ASMs do not address epileptogenesis, the disease process that leads to epilepsy [8,9]. Understanding of mechanisms

involved in epileptogenesis will play an important role in the development of novel drugs that target the epileptogenic process.

2. Epileptogenesis

Epileptogenesis is poorly understood multifaceted chronic process that alters normal brain into an epileptic brain capable of generating spontaneous recurrent seizures (SRSs) [10]. Some of the common processes involved in epileptogenesis include, neuroinflammation, neuronal cell death in the hippocampus and temporal lobe, bioenergetic dysfunction, altered neuroplasticity, blood-brain barrier (BBB) disruption, astrogliosis, microglial activation, and infiltration of inflammatory cells into brain parenchyma. Injections of chemo-convulsant, such as kainic acid and pilocarpine, or repetitive electrical stimulation of the hippocampus or amygdala, can lead to a chronic epileptic state with robust convulsive SRSs in animal models of acquired epilepsy and their use will help tremendously in better diagnosis, treatment, and prevention of human epilepsy. Anticonvulsant drugs mostly relieve symptoms and prevent the occurrence of future seizures in epileptic patients rather than inhibiting and or modulating the neuroinflammatory processes of epileptogenesis [9]. Development of targeted therapeutic strategies beyond conventional anticonvulsant/antiseizure treatments is needed to address epileptogenesis and epilepsy.

In general neuroinflammation is beneficial because it promotes homeostatic neurogenesis [11,12], provides protection against loss of axons and neurons [13], and promotes axonal regeneration [14,15], but the chronic neuroinflammation has been shown to be detrimental in numerous neurological disorders including Parkinson's disease, Alzheimer's disease, meningitis, multiple sclerosis, encephalitis [16] and epilepsy [17–19]. Despite the absence of pathogens, neuroinflammation in epilepsy is triggered by an abnormal increase in proinflammatory mediators [20] or by endogenous inducers (damage-associated molecular patterns [DAMPs]) produced and released by brain cells undergoing stressful events termed as sterile inflammation [21]. DAMPS such as, adenosine triphosphate (ATP), high mobility group box1 (HMGB1), reactive oxygen species (ROS), K^+ efflux, advance glycation end products (AGEs), S1100b (a Ca^{2+} binding protein), or migration inhibitory factor-related protein 8 (MRP8) are known to induce formation of inflammasome, a multi-molecular protein complex [22–24].

3. Inflammasomes

Tschopp and colleagues coined the term inflammasome in 2002 to define a high molecular weight protein complex that mediated the activation of inflammatory caspases [25]. An inflammasome is comprised of a sensor protein (a cytoplasmic pattern-recognition receptors (PRRs) classified by its protein domain structures), an adapter protein (apoptosis-associated speck-like protein containing a CARD [ASC]), and pro-caspase-1 as an effector protein [26]. Typically, inflammasomes are named after their cytoplasmic pattern-recognition receptors (PRRs) sensor proteins that are either of a NLR family (a nucleotide binding domain (NBD) combined with a leucine-rich-repeat-containing receptor (LRR-CR) protein) or an ALR family (an absent in melanoma 2 (AIM2)-like receptor (ALR) protein). Most pertinent inflammasomes belong to the NLR family subgroups containing pyrene domain (NLRP) or CARD domain (NLRC) proteins. The best known inflammasomes are NLRP1; NLRP2; NLRP3; NLRP6, NLRP7; NLRP12; NLR-family apoptosis inhibitory protein (NAIP); NLR-family, CARD-containing 4 (NLRC4); AIM2; and Pyrin inflammasomes. Several studies have shown that the central nervous system (CNS) is equipped with different inflammasome subtypes, however, their expression profiles vary among CNS cell types [27–31]. NLRP1 is predominantly expressed in neurons and oligodendrocytes [32–35], NLRP2 in astrocytes [36,37], NLRP3 in microglia [38–41], NLRC4 in astrocytes [42,43] and the AIM2 in neurons [44,45]. The NLRP3 also known as cryopyrin, or NALP3 is the most widely studied and best characterized inflammasome. The NLRP3 protein has an N-terminal Pyrin domain (PYD), a central ATPase domain known as NACHT that comprises the NBD, a helical domain 1 (HD1), a winged helix domain (WHD), a helical domain 2 (HD2), and a C-terminal LRR domain [46].

NIMA (never in mitosis A)-related kinase 7 (NEK7), is a serine/threonine kinase that modulates microtubule stability, mitotic spindle formation and cytokinesis and has now been identified as an important component of the NLRP3 inflammasome [47,48]. NEK7 senses reactive oxygen species (ROS), K⁺ efflux, lysosomal destabilization, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling mediated activation of NLRP3 [49,50]. A cryo-EM structure of NLRP3-NEK7 protein complex suggests that the first half of the NEK7 C-terminal interacts with the LRR domain of NLRP3 and the second half with the NBD and HD 2 domains of NACHT [46]. The binding of NEK7 alone is not sufficient to activate NLRP3. In addition, ATP needs to be bound to the NBD domain and used to phosphorylate S195 in NEK7 prompting NLRP3 to adopt a modified conformation that drives oligomerization and activation of the NLRP3 complex [51]. Thus, NEK7 plays a licensing role in NLRP3 activation rather than serving as the sole activator [46].

3. Activation of the NLRP3 Inflammasome

Physiological activation of NLRP3 is tightly regulated to avoid uncontrolled inflammatory responses and is beneficial against invading pathogens and tissue damage whereas abnormal or chronic activation plays a detrimental role in cellular and body health. As depicted in Figure 1, NLRP3 inflammasome activation can occur via canonical, non-canonical and alternative pathways [52]. Optimal activation of NLRP3 via canonical pathway requires priming step/Signal 1, initiated by the detection of extracellular PAMPs and endogenous cytokines by the PRRs, which then upregulates the NF-κB-mediated transcription of NLRP3, pro-IL-1β and pro-IL-18 [53]. In addition, priming also regulates NLRP3 at post-transcriptional level through DNA methylation, protein acetylation, and the use of microRNAs. For example, Wei et al. reported that the NLRP3 expression was increased through NLRP3 promoter demethylation in response to *Mycobacterium tuberculosis* infection [54]. It has been revealed that the NLRP3 induction by lipopolysaccharide (LPS) priming is decreased by binding of RNA-binding protein Tristetraprolin [55] and miRNA-223 [56] to 3'UTR of NLRP3. Moreover, priming also involves various post-translational modifications (PTMs) of the NLRP3 protein, such as ubiquitination and phosphorylation, that silence NLRP3 for subsequent activation by second signal.

The second activation step or Signal 2, is the assembly of the inflammasome proteins triggered by sensing intracellular PAMPs/DAMPs through a combination of important and related events such as, activation of the purinergic receptor P2X7 by ATP, cathepsin release following lysozyme rupture, opening of Ca²⁺ channels to allow ion flux, mitochondrial dysfunction, ROS formation, Golgi apparatus disassembly and endoplasmic reticulum stress (ERS) [57]. Once activated, oligomerization of the NLRP3 inflammasome involves two homotypic protein-protein interactions. First, the PYD domain of NLRP3 protein interacts with the adaptor protein ASC via PYD-PYD interactions and the CARD domain of ASC interacts with the CARD domain of pro-caspase 1 to recruit it to the NLRP3 inflammasome [58]. The activated NLRP3 inflammasome is thought to induce conformational changes that generate active caspase-1 (Casp1), which converts pro-interleukin-1β (pro-IL-1β) and pro-interleukin-18 (pro-IL-18) to mature bioactive IL-1β and IL-18 [53]. Additionally, Casp1 cleaves the protein gasdermin D (GSDMD) to generate N-terminal GSDMD (N-GSDMD) [59]. After cleavage, N-GSDMD oligomerizes in the cell membrane to form pores, allowing IL-1β and IL-18 to leave the cell and effectively execute a highly inflammatory form of cell death that is termed pyroptosis [25,60].

In the non-canonical pathway for NLRP3 inflammasome activation where intracellular LPS that have been generated by Gram-negative bacteria (i.e., *Citrobacter rodentium*, *Escherichia coli*, *Legionella pneumophila*, *Salmonella typhimurium*, and *Vibrio cholerae*) are directly recognized by the CARD domain of caspase-11 in mice and caspase-4/5 in humans, ultimately leading to IL-1β and IL-18 release through the activation of the NLRP3-ASC-Casp1 pathway [61–64].




Figure 1. Schematic illustration of the mechanism regulating NLRP3 inflammasome activation in canonical, non-canonical and alternate pathway. Optimal activation of NLRP3 requires two steps. The first step is priming which is initiated by extracellular PAMPs and endogenous cytokines by the PRRs, which then upregulates the NF-κB-mediated transcription of NLRP3, pro-IL-1β and pro-IL-18. The second step is activation which includes canonical and non-canonical pathways. The canonical pathway is triggered by multiple pathogens and inflammatory agents through a combination of important and related events such as, activation of the purinergic receptor P2X7 by ATP, cathepsin release following lysozyme rupture, opening of Ca²⁺ channels to allow ion flux, mitochondrial dysfunction, ROS formation, Golgi apparatus disassembly and endoplasmic reticulum stress. Once activated, oligomerization of the NLRP3 inflammasome is thought to induce conformational changes that generate active caspase-1, which converts pro-IL-1β and pro-IL-18 to mature bioactive IL-1β and IL-18. Additionally, Casp1 cleaves the protein gasdermin D to generate N-terminal gasdermin D to form pores, allowing IL-1β and IL-18 to leave the cell and effectively execute a highly inflammatory

form of cell death that is termed pyroptosis. In the non-canonical pathway where intracellular LPS are directly recognized by the CARD domain of caspase-11 in mice and caspase-4/5 in humans, ultimately leading to IL-1 β and IL-18 release through the activation of the NLRP3-ASC-Casp1 pathway. The alternative pathway of activation is elicited by TLR4 agonists like LPS, which activates the TLR4-TRIF-RIPK1-FADD-Casp8 signaling. Casp8 activates the NLRP3 inflammasome but lacks ASC speck formation, pyroptosis induction, or K⁺ efflux.

The third or the alternate pathway of NLRP3 inflammasome activation exists in both human and porcine monocytes, but not in murine cells [65]. In this alternate pathway, NLRP3 assembly occurs upon activation of toll-like receptor 4 (TLR4) in response to LPS and requires the TIR-domain-containing adapter-inducing interferon- β (TRIF)-receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-Fas-associated protein with death domain (FADD)-caspase-8 signaling cascade, to activate the NLRP3 inflammasome leading again to cleavage of pro-IL-1 β to produce mature and active IL-1 β [66]. In contrast to classical (canonical and non-canonical activation pathways), the alternative pathway lacks ASC speck formation, pyroptosis induction, or K⁺ efflux [67].

4. NLRP3 Inflammasome Involvement in Epilepsy

An increase in the NLRP3 activity has been shown in the brain of individuals with epilepsy and in animal models of epilepsy [68–75]. Meng et al. first documented a significant increase in NLRP3 inflammasome in the amygdala kindling-induced murine model of seizures [70]. NLRP3 inflammasome activation in kainic acid (KA)-induced epileptic rats became evident when significant neuronal loss was noticed along with elevated levels of mature IL-1 β , active caspase 1 and expression of the NLRP3 protein [68]. Magalhães et al. documented enhanced expression and activation of the NLRP3 inflammasome in organotypic slices as an ex vivo model of epilepsy [76]. In another in vivo study NLRP3 inflammasome activation was significantly correlated with epileptic neuronal apoptosis [72]. Jiang and colleagues revealed that an increase in NLRP3 gene transcription is due to binding of Stat3 acetylation of the histone H3K9 site of the NLRP3 promoter resulting in increased NLRP3/caspase-1-mediated hippocampal neuronal cell death in epileptic mice [77]. NLRP3 inflammasome activation has also been reported in the hippocampus of pentylenetetrazole (PTZ)-induced epileptic mice and LPS-induced BV2 microglial cells [78]. Yue and colleagues reveal that the NLRP3 inflammasome components are highly expressed in neurons, astrocytes, and microglia in the epileptogenic zone of patients with temporal lobe epilepsy (TLE), a form of epilepsy associated with hippocampal neuronal atrophy and in the hippocampi of a mouse model of status epilepticus (SE)-induced by pilocarpine [73]. Furthermore, they also reported that NLRP3 inflammasome activation may promote ER stress and trigger the progression of TLE. In another study, they showed that levels of RevErbA, a putative down regulator of the NLRP3 inflammasome, are diminished in the epileptogenic area of patients with mesial TLE (mTLE) [79]. Wu and colleagues reported that the number of NLRP3-positive cells in the temporal lobe cortical tissues of refractory epilepsy patients was significantly higher than the control group [80]. They also demonstrated increased levels of NLRP3 and IL-1b in the blood of patients with refractory TLE. Furthermore, NLRP3 has been reported to be upregulated and expressed by both neuronal and glial cells in the sclerotic hippocampi of mTLE patients which may contribute to the overexpression of hippocampal caspase -1 and IL-1b [81]. A study from Wu et al. provided the first evidence that autophagy plays a crucial role in NLRP3 inflammasome activation in the development of epilepsy [82]. NLRP3 expression was also found to be increased in the children with febrile seizures [83]. A recent report by Zhang et al. confirmed that activation of NLRP3 inflammasome enhances the expression of adenosine kinase to accelerate epilepsy in mice through CREB/REST/Spa signaling pathway [84]. Pohlentz et al. demonstrated that NLRP3 and its associated signaling molecules are activated in brain tissue samples of patients with TLE and in the pilocarpine and KA-induced SE mouse models [85].

Tan et al. demonstrated for the first time the elevated expression of NLRP1 and active caspase-1 in surgically resected hippocampi of patients with mTLE compared to a healthy group [33]. Furthermore, NLRP1-mediated caspase-1-dependent neuronal pyroptosis within the hippocampus

was impeded in NLRP1/capase-1 -deficient rats. Decreased frequency and severity of seizures were also observed in these rats. Differential gene expression analysis of the RNAseq data revealed the upregulation of *NLRP1* mRNA in hippocampal tissues resected from patients with mTLE-hippocampal sclerosis [86]. Increased expression of NLRP1 inflammasome was observed in the sclerotic hippocampi of mTLE patients [81]. Gao et al. reported an elevated expression of the NLRP1 inflammasome in hippocampi from the pentylenetetrazol (PTZ) kindling model of epilepsy in rats [87]. Recently, the expression of *NLRP1* and *NLRP3* mRNAs were significantly increased in the animal model of epilepsy induced by intrahippocampal injection of KA compared to controls [88].

5. Current Antiseizure Medications for the Treatment of Epilepsy

Since epilepsy is a complex multifaceted disease, no single ASM has emerged over time as the primary treatment. Instead, individualized treatment is given to a patient with the choice of ASM dependent upon the specific epileptic syndrome (6,87). The majority of the 30 currently existing ASMs are effective and better tolerated by patients (6) and are known to target either the GABAergic system or voltage-gated channels to curb the abnormal neuronal activity in the brain during seizures [89–91]. Some of these drugs are illustrated in Figure 2, emphasizing the diversity in their chemical structures. It is important to note that even with the use of new ASMs as many as 30% of epileptic patients still fail to benefit from ASM treatments (5,6, 132–135).




Figure 2. Chemical structures of clinically approved antiseizure medications discussed in this review.

5.1. Currently Preferred ASM Used to Treat Epilepsy

Valproic acid, an 8-carbon 2-chain fatty acid is the drug of choice for both adults and children suffering from epilepsy [92]. At a therapeutic range (50-100 mg/ml), it attenuates the high frequency firing of cortical and spinal cord neurons via the blockade of Na^+ , K^+ , and Ca^{2+} channels [93]. Because

of valproate-induced hepatotoxicity, ethosuximide (3-ethyl-3-methyl pyrrolidine-2,5-dione) is considered a safer alternative [94]. This drug acts to disrupt the abnormal electrical activity of the thalamocortical circuitry by blocking T-type Ca^{2+} channels [90]. Clonazepam (1,3-Dihydro-2H-1,4-benzodiazepin-2-one) a long-acting benzodiazepine can reduce the number of epileptic seizures [95] by increasing neurotransmitter γ -aminobutyric acid (GABA) to decrease any abnormal electrical nerve activity in the CNS that might be contributing to seizures [96]. Clonazepam may lose its effectiveness over time due to the development of tolerance. One of the original ASMs, phenobarbital, is still used to prevent all types of seizures, but is not used to treat absence seizures. It exhibits its antiepileptic effect by increasing the inhibitory drive of GABA [97], and despite its sedative side effects, it is still widely used due to its low cost, particularly in developing countries [98]. A recent report suggests that levetiracetam (LEV), a novel ASM exerts neuroprotective by inhibiting the expression of proinflammatory molecules, such as TNF- α , IL-6 and IL-1 β [99,100]. Lamotrigine, a synthetic phenyl triazine, is used alone or with other medications to treat epileptic seizures in adults and children [101]. Though its mechanism of action is not entirely understood, it appears to inhibit the release of excitatory neurotransmitters such as glutamate and aspartate triggered by voltage-sensitive Na^{+} channels and voltage-gated Ca^{2+} channels in neurons [102]. Results from Marson et al. support the continued use of lamotrigine as the best first-line treatment option for patients newly diagnosed with focal epilepsy [103]. Topiramate, a sulfamate-substituted monosaccharide, reduces the frequency and duration of seizures and is used in the treatment of certain types of epilepsy. Topiramate's antiepileptic effect mediated through several mechanisms, including (i) blockade of voltage-sensitive Na^{+} channels and/or Ca^{2+} -channels, (ii) enhancement of GABA-mediated Cl^{-} fluxes into neurons, (iii) increases in K^{+} conductance and (iv) inhibition of glutamate-mediated neurotransmission [104]. Gabapentin, designed as a lipophilic analogue of GABA can easily cross the BBB to increase brain synaptic GABA [105] and to suppress influx of Ca^{2+} ions into neurons via voltage-dependent Ca^{2+} channels. Phenytoin has been used for several decades in the treatment of children with partial and generalized tonic-clonic seizures via a membrane potential-dependent blockade of Na^{+} channels. In addition to working through some of the mechanisms described above, zonisamide also reduces the concentration of free radicals and thus may be effective against some primarily generalized seizures, such as tonic-clonic, absence, and tonic seizures. [106]. Oxcarbazepine, a keto analog of carbamazepine is a safer and more efficacious drug for treating partial onset seizures in both adults and children epileptic patients and its antiepileptic activity is mediated by blocking of neuronal ion channels [107]. Eslicarbazepine acetate, a third generation ASM has been proven effective when used in combination with other drugs to reduce the number of seizures in drug resistant focal epilepsy [108].

There are several other drugs available for the treatment of epilepsy, which include lacosamide, brivaracetam, and perampanel [109]. Additionally, new treatments have been developed such as vagal nerve stimulation and ketogenic diets [110–112]. These new therapies and drugs have the potential to revolutionize epilepsy treatment, but much research is needed before they can be approved for wider use.

5.2. The Limitations of Current Clinical ASMs and Potential New Avenue for Drug Development in Epilepsy

Despite their effectiveness, ASMs have serious and life-threatening side effects and higher percentage of epileptic patients develop resistance over time. Some of the generalized side effects of ASMs include depression, suicidal thoughts, mood change or hostility, nausea, vomiting, coordination problems, sleepiness, and dizziness and hepatotoxicity. Certain epilepsy medications can also interact with other drugs, such as pain killers or antibiotics, leading to serious consequences. Pharmacodynamic reaction of lamotrigine with carbamazepine can lead to carbamazepine intoxication [113]. Other ASMs such as phenobarbital, carbamazepine, primidone, and phenytoin can cause an imbalance in the patient's calcium and vitamin D levels, leading to osteoporosis [114]. Due to restrictive permeability and active efflux of some ASMs including phenobarbital and phenytoin, the BBB limits the delivery and/or the transport of ASMs to the brain [115]. As the underlying cause(s)

of epilepsy are not fully understood, the drugs developed for treating epilepsy are primarily aiming at controlling seizures and not at addressing the underlying cause of the disease. Given the status, there is a need for a more effective therapy for epilepsy.

6. NLRP3 Inflammasome in Epilepsy

Recent research suggest that increased activity of NLRP3 contribute to the development and progression of epilepsy [68,70,71,73–75,116], hence inhibiting the activity of NLRP3 activity may reduce inflammation-caused epileptic injuries and potentially may improve symptoms [88]. NLRP3 inhibitors, a potential new class of drugs might have fewer side effects, be more effective in a larger number of patients and could target the underlying causes of epilepsy. Additionally, NLRP3 inhibitors have the potential to be effective in treating other inflammatory and autoimmune disorders such as gout, Alzheimer's disease, and certain cancers, which makes the development of NLRP3 inhibitors a promising area of research [117–120].

There are several approaches that can be taken to develop NLRP3 inhibitors, including: i). Small molecule inhibitors: These are drugs that can bind to specific sites on the NLRP3 protein and prevent it from activating. These can be identified through high-throughput screening of chemical libraries. ii) Peptide inhibitors: These are short chains of amino acids that can bind to the NLRP3 protein and inhibit NLRP3 inflammasome activation. These can be identified through phage display or other peptide-based screening methods. iii). Antibodies: These are proteins that can bind to specific regions of the NLRP3 protein and prevent it from activating. These can be generated through antibody-based screening methods. iv). RNA interference: This is a method for silencing specific genes by targeting their RNA. It can be used to target the NLRP3 gene and prevent it from being expressed.

Once potential NLRP3 inhibitors have been identified, they can be further tested in cell-based assays and animal models to evaluate their efficacy and safety before moving on to clinical trials.

6.1. NLRP3 Inhibitors in Preclinical and clinical Trial Phase

Since the role of NLRP3 inflammasome pathway in the pathogenesis and progression of epilepsy has been well documented, the development of NLRP3 inhibitors as a potential therapeutic target for the treatment of seizures and epilepsy is urgently needed. In epileptic animal models, knock-down of *NLRP3* has been shown to reduce neuronal cell death and attenuated the chronic seizure phenotype [70,72,80]. Inhibition of the NLRP3 using the pump-mediated in vivo infusion of nonviral siRNA provides neuroprotection in rats following amygdala kindling-induced status epilepticus [70]. Recent studies have reported several inhibitors that directly or indirectly target NLRP3 inflammasome can reduce inflammation, promote neuroprotection and decrease seizures [121–123]. Some of the NLRP3 inhibitors depicted in Figure 3 could help in improving our understanding of the underlying biological mechanisms that contribute to epileptic seizures and thus could help in improving our ability to diagnose and treat the condition. Several clinical trials are underway, exploring the efficacy and safety of NLRP3 inhibitors in patients with chronic, drug-resistant epilepsy.




Figure 3. Chemical structure of different NLRP3 inflammasome inhibitors discussed in this review.

MCC950 (N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl) amino] carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide) also known as CP-456, 773 or cytokine release inhibitory drugs 3 (CRID3) is best characterized and potent NLRP3 inhibitor. It blocks both canonical and non-canonical NLRP3 inflammasome activation, but no inhibitory effect has been reported on AIM2, NLRC4 or NLRP1 inflammasome activation [124]. Mechanistically, MCC950 does not inhibit priming step of NLRP3 activation as well as K^+ efflux, Ca^{2+} flux, NLRP3-NLRP3, NEK7-NLRP3 or NLRP3-ASC interactions [124], but it directly interacts with Walker B motif of the NACHT domain with a high affinity non-covalent interaction, blocking NLRP3 from hydrolyzing ATP to ADP and conformational changes critical for NLRP3 oligomerization and activation [125,126]. Preclinical studies have shown promises in several different types of inflammatory diseases, including Crohn's disease [127], ulcerative colitis [128], Alzheimer disease [129,130], rheumatoid arthritis [131], Huntington's disease [132], cardiovascular disease [133] and multiple sclerosis [134]. In bone marrow-derived macrophages (BMDMs), MCC950 showed inhibition of IL-1 β release at IC_{50} of 7.5 nM, while in human monocyte derived macrophages (HMDM) IC_{50} is 8.1 nM [124,135]. MCC950 also reduces brain injury and inflammation in a mouse model of traumatic brain injury [136]. Recent evidence showed that in an in vitro SH-SY5Y model and in vivo model of cerebral trauma induced by PTZ, the administration of MCC950 significantly provided a protective effect, reduced epileptic neuronal apoptosis by inhibiting NLRP3 inflammasome activation [72]. Positive correlation between NLRP3 and ERS has

been observed in several models of epilepsy, including temporal lobe epilepsy, and in human brain tissues from patients with epilepsy [137–140], suggesting that it may be an underlying mechanism in the development of seizures. Recently, Yue et al. demonstrated that MCC950 significantly reduced the levels of NLRP3 and expression of ERS related markers in the hippocampi of pilocarpine-induced SE mice [73]. MCC950 has been shown to inhibit the NLRP3 inflammasome activation in KA-induced SE mice and KA-treated astrocytes [84]. Furthermore, clinical trials of MCC950 have also been initiated to evaluate its safety and efficacy conducted [141]. MCC950 was initiated in a phase II clinical trial for rheumatoid arthritis, but it was discontinued due to liver toxicity.

CY-09 (4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl) phenyl] methyl] -5-thiazolidinylidene] methyl] benzoic acid) is a specific and direct inhibitor of NLRP3 that inhibited its ATPase activity and activation by binding to the Cys172 residue in the Walker A motif of the NACHT domain of NLRP3 [142]. CY-09 demonstrated favorable pharmacokinetic properties for safety, stability, and oral bioavailability. Previous studies have suggested that CY-09 could be used for the treatment of NLRP3 inflammasome associated diseases, including type 2 diabetes, gout, thrombosis, cryopyrin-associated autoinflammatory syndrome (CAPS) mouse models and other diseases [142–144]. In addition, CY-09 inhibited monosodium urate (MSU), nigericin and ATP-mediated inflammation as well as IL-1 β secretion in BMDMs at the doses of 1-10 mM. CY-09 blocks the release of inflammatory cytokines, intracellular Ca²⁺ via inhibiting TRAP1-mediated activation of NLRP3 inflammasome [143]. Shen et al. reported that CY-09 inhibited the NLRP3 driven neuroinflammation in PTZ induced kindling mouse model, a chronic model of generalized seizures [145]. CY-09 repressed the expression of NLRP3, IL-1 β and IL-18 in injured brain tissue in the rat TBI models [146]. The findings from Wang et al. showed that CY-09 attenuates depression-like behaviors by inhibiting the NLRP3-mediated neuroinflammation in LPS-induced mice [147]. In clinical trial, CY-09 was found to be effective in reducing the number and severity of seizures in people with focal epilepsy when compared to placebo. However, confirmatory studies are worthy of broadening its potential in treating epilepsy.

Glyburide, a sulfonylurea also known as glibenclamide, is an FDA-approved ATP-sensitive K⁺ (K_{ATP}) channel inhibitor to treat type 2 diabetes mellitus [148]. In 2001, Perregaux et al. reported first time that glyburide inhibits IL-1 β release in LPS-activated human monocytes [149]. In another study, glyburide was shown to inhibit IL-1 β release during bronchial hypo responsiveness through K_{ATP} channels [150]. Glyburide has been reported to exhibit anti-inflammatory effects mainly by inhibition of microbial ligand-induced NLRP3 inflammasome activation and IL-1 β secretion by blocking K_{ATP} channels [151]. Glyburide has been shown to block NLRP3 inflammasome activation and IL-1 β production stimulated by islet amyloid polypeptide associated with type 2 diabetes [152]. In human pancreatic islets, glyburide partially prevented the increased expression of NLRP3 and IL-1 β induced by LPS and ATP [153]. Recent study has reported that glyburide blocked the assembly and activation of NLRP3 inflammasome and IL-1 β release by dampening the binding of NEK7 to NLRP3 in ventilator-induced lung injury [154]. Research has shown that it plays a dual role in attenuating cerebral edema and improving long-term cognitive function in pilocarpine-induced mouse model of status epilepticus [155]. Acute administration of glyburide, 30 min prior to the PTZ, significantly increased the seizure threshold in intravenous PTZ mode of mice [156].

Beta-hydroxybutyrate (BHB), one of the ketone bodies, has been shown to reduce inflammatory cytokines release mediated by NLRP3. It has been studied for its potential therapeutic benefits in various inflammatory diseases, including epilepsy [157–161]. The mechanism of action by which BHB acts as an NLRP3 inhibitor is not fully understood. However, it is thought that BHB may inhibit NLRP3 inflammasome activation by modulating the production of reactive oxygen species (ROS) and by reducing the levels of ATP in the cell. Beta-hydroxybutyrate also inhibits the NLRP3 inflammasome by preventing K⁺ efflux and reducing ASC oligomerization and speck formation [162]. Kim et al. reported that BHB reduced the spontaneous recurrent seizures in spontaneously epileptic Kcna1-null mice [163]. Furthermore, BHB decreased seizure duration and frequency in 6-Hz induced seizure model of refractory epilepsy [164]. It's important to note that more research is needed to fully understand the mechanism of action and potential clinical applications of BHB as an NLRP3 inhibitor.

RRx-001 (1-bromoacetyl-3,3-dinitroazetidine) was initially developed as an anticancer agent by the aerospace industry [165] has been extensively studied in vitro and in vivo models of several inflammatory diseases including Alzheimer's disease, stroke, multiple sclerosis, pulmonary fibrosis, and IBD [166]. In a randomized Phase 2 trial called (PREVLAR; NCT03699956), RRx-001 administration in 53 first-line head-and-neck cancer patients dramatically improved the incidence, duration, time to onset and severity of oral mucositis. RRx-001 has been safely evaluated in over 300 comorbid, treatment-resistant cancer patients in 12 clinical trials, including in an ongoing phase 3 trial for the treatment of small cell lung cancer (REPLATINUM; NCT03699956) [165]. RRx-001 is the highly selective and most clinically advanced small molecule NLRP3 inhibitor that has been safely evaluated in over 300 patients [165]. Mechanistically, RRx-001 covalently binds to cysteine 409 of NLRP3 on the central NACHT domain of NLRP3, which inhibits the assembly and activation of the NLRP3 inflammasome [165,166]. The BBB-penetrant nature of RRx-001 inhibitor and the preclinical assessment of this inhibitor in various neurodegenerative diseases [167] advances the possibility of this uncharged small molecule inhibitor to be tested soon in epilepsy.

Several other classes of compounds that have been explored for NLRP3 inflammasome inhibition includes flavonoids, chalcone and boron-based compounds. Amentoflavone, a naturally occurring bioflavonoid [78] and semaglutide, a glucagon like peptide-1 [74] were reported to affect epileptogenesis and reduce seizures via their neuroprotective effects because of NLRP3 inflammasome inhibition in PTZ-kindled mice. Sun et al. revealed that endogenous as well as exogenous IL-10 downregulates IL-1 β production in microglia in mice exposed to epileptogenic injury thorough STAT3-dependent inhibition of NLRP3 inflammasome activity [168].

Licochalcone B, Isoliquiritigenin, Cardamomin are the natural chalcone-based compounds that showed promising NLRP3 inflammasome inhibitory effects. Licochalcone B binds with NEK7 preventing the interaction with NLRP3 which is important for the NLRP3 inflammasome activation [169]. Isoliquiritigenin isolated from *Glycyrrhiza uralensis* has been reported to activate the Nrf2 mediated antioxidant signaling preventing the activation of NF- κ B and NLRP3 inflammasome [170,171]. Cardamomin reduced the protein levels of NLRP3, Casp1 and IL-1 β in 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis mice [172]. BC7, BC23 and NBC6 are potent oxanorbornenes molecules developed as potent NLRP3 inflammasome inhibitors. Among these three molecules, compound NBC6 showed the most potent inhibition of IL-1 β release from THP-1 monocytes with an IC₅₀ of 574 nM. BC7 and BC23 showed the IC₅₀ value of 1.16 μ M and 2.29 μ M, respectively for the inhibition of IL-1 β release [13,14].

Huperzine A, a naturally occurring sesquiterpene alkaloid and valproic acid, one of the most prescribed medications against epilepsy have been shown to inhibit activation of NLRP3 inflammasome in the rat KA-induced model of epilepsy in a ROS-dependent manner [173]. Recently, furosemide (4-chloro-5-sulphonyl-N-furfuryl-anthranilic acid), a diuretic drug, has been shown to decrease the NLRP3 as well as NLRP1 level significantly when treated in combination with valproic acid in KA-induced epileptic rats [174].

Studies from Li and coworkers have reported that ibuprofen may have antiepileptic and neuroprotective effects in the rat model of PTZ-induced epilepsy via inhibiting NLRP3 inflammasome activation [175]. Rapamycin, an inhibitor of mTOR signaling have been reported to alleviate the symptoms of seizures, anxiety, and depression in PTZ-kindled rats by inhibiting NLRP3 inflammasomes and ROS production [176]. Chaihu-Longgu-Muli decoction, a well-known ancient formula in traditional Chinese medicine could significantly suppress the frequency and duration time of epileptic seizures, reduce the expression of NLRP3, Caspase-1, TNF- α and IL-1 β [177]. Natural products such as parthenolide and oridonin from *Rabdosia rubescens*, were also able to inhibit the NLRP3 inflammasome [178,179]. It was observed that oridonin binds covalently with the Cys279 of the NLRP3 NACHT domain. This binding prevents the interaction between NLRP3 and NEK7 which is essential for the NLRP3 inflammasome assembly and activation [178]. Recently, oridonin has been shown to rescue kanamycin related hearing loss by inhibiting NLRP3 inflammasome activation [154,180]. BAY 11-7082, an NF- κ B inhibitor has also reported to inhibit the NLRP3 ATPase activity in macrophages independent of their inhibitory effect on NF- κ B activity [179].

Curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione)), a polyphenolic compound present in turmeric (*Curcuma longa*) exhibits an antioxidant, anti-inflammatory and neuroprotective properties and its beneficial effect on epilepsy has been shown in many preclinical studies [181–185]. Curcumin has been reported to inhibit IL-1b release and prevent inflammation via inhibition of NLRP3 [186] and suppressed KA-induced epileptic syndrome via inhibiting NLRP3 inflammasome activation in Sprague Dawley rats [68].

MicroRNAs (miRNAs) are endogenous ~20–23 nucleotide long non-coding RNA that bind to the 3' untranslated region (3'UTR) of protein-coding mRNAs to regulate their translation and thus can have significant impacts on cellular processes. Several miRNAs that can target different components of the NLRP3 inflammasome and modulate its activity have been identified. For example, miR-223 has been shown to target the NLRP3 inflammasome in the brain and reduce neuroinflammation and neuronal damage [187] and inhibit NLRP3 expression and reduce inflammation in various disease models, including arthritis, atherosclerosis, and myocardial infarction [56,188,189]. miR-29c modulates NLRP3 inflammasome to impair microglial inflammatory responses [190], miR-17-5p ameliorated NLRP3 inflammasome activation mediated hypoxic-ischemic brain injury in rat [191], miR-138-5p overexpression in epileptic neuron inhibits NLRP3 by directly binding with ubiquitin-specific peptidase 47 (USP47), a positive regulator of NLRP3 [192]. miR-29a-5p mimics protect TBI-induced BBB dysfunction via suppressing NLRP3 inflammasome activation [193]. Other miRNAs, such as miR-23a, miR-let-7e, miR-30e and miR-223, have also been found to inhibit the NLRP3 inflammasome and reduce inflammation [194]. Overall, use of miRNAs as NLRP3 inhibitors holds promise as a potential therapeutic approach for treating a range of inflammatory and autoimmune diseases. However, more research is needed to fully understand the mechanisms underlying miRNA regulation of NLRP3 and to develop effective and safe miRNA-based therapies for different diseases.

6.2. NLRP3 Inflammasome Inhibitors and Their Limitations as Remedial Strategies

NLRP3 inhibitors have been investigated as potential drugs for the treatment of various inflammatory and autoimmune diseases. Off-target effects are the significant drawback of using NLRP3 inhibitors. For example, MCC950 at high micromolar concentrations could inhibit carbonic anhydrase 2 [195] and block Cl⁻ efflux from nigericin-activated macrophages [142]. CY-09 has been reported to affect cytochrome P450 enzymes [122]. Another inhibitor, oridonin has several targets e.g., AKT/2, c-Myc, p39 and MAPK [196]. Since NLRP3 is involved in many important cellular processes, including immune defense and tissue repair, blocking its activity could lead to unintended consequences including impairing pathogen clearance and thus increasing the risk of infection. MCC950 has been examined in phase II clinical trial for the treatment of rheumatoid arthritis, but the trial was discontinued due to hepatic toxicity [52]. NLRP3 plays a crucial role in the immune system, blocking its activity may also interfere with the body's ability to fight infections and heal wounds.

Future studies should take advantage of available cryo-EM and crystal structures of NLRP3 bound to NEK7 [46], and focus on the development of structure-guided direct inhibitors with improved specificity and potency. Recently, Agarwal et al. rationally designed MCC950-derivative compounds [181,197,198]. These compounds were found to be potent and selective NLRP3 inhibitors with good pharmacokinetic profile and high oral bioavailability in mice. In addition, another NLRP3 inhibitor NT-0796 with differentiated novel chemistry that provides unprecedented potency and potential for prolonged pharmacodynamic effect, with the ability to cross the BBB [199]. Since nanoparticle (NP)-based drug delivery is an emerging area of research in the field of nanomedicine and immunotherapy due to their intriguing properties such as target site specificity, systemic stability, and low toxicity [200], Mancuso et al. analyzed the effect of Glyburide-loaded nanovesicles (GNVs) on NLRP3 inflammasome activation in LPS and nigericin-activated THP-1 cell model [201]. Their results confirm that GNVs were able to inhibit IL-1b secretions more efficiently than free glyburide. Recently, Kulkarni and coworkers synthesized and analyzed MCC950 loaded nanoparticles (MCC NPs) and found that MCC NPs showed a significant reduction in IL-1b secretions in vitro and in vivo [202]. Tang et al. developed a unique delivery platform encapsulated with colchicine (VHPK-PLGA@COL), which exhibited improved biosafety and sustained drug

release along with the gradual degradation of PLGA and PEG as confirmed both in cell culture and in animal models [203]. The inhibitory effect of VHPK-PLGA@COL on NLRP3 and its downstream molecules was more pronounced than that of free colchicine. Exosome-like nanoparticles from ginger rhizomes strongly inhibited NLRP3 inflammasome activation [204]. Another group prepared garlic chive-derived vesicle like nanoparticle which exhibit potent anti-NLRP3 inflammasome activity [205]. Moreover, dexamethasone-loaded ROS-responsive polymer nanoparticles prepared by a modified emulsion approach had a strongest ability to inhibit the expression of NLRP3, caspase1, and IL-1b [206]. It has been reported that nanoparticles itself trigger the NLRP3 inflammasome activation [207–210]. However, the formation of protein corona layer on lipid NPs caused a significant reduction in NLRP3 inflammasome activation and controls the toxicity, biodistribution, and cellular uptake [211]. Chalcones are natural compounds with α , β unsaturated carbonyl group (Michael acceptor) found in many plants and have gained attention for their medicinal properties [212,213]. We and others investigated some chalcones for their potential as NLRP3 inhibitors [214,215]. Our preliminary data encourage further development of more potent NLRP3 inhibitors based on this chalcone scaffold which could lead to the development of novel treatments for epilepsy and other inflammatory diseases.

7. Conclusions and Perspectives

Scientific evidence support the role of NLRP3 in epileptic seizures and use of NLRP3 inhibitors seems promising in understanding the biological mechanisms behind epilepsy, leading to development of biomarkers for early detection and more targeted, effective treatments to reduce seizures in high-risk individuals with epilepsy. Clinical trials are underway to investigate the efficacy and safety of these inhibitors in humans, and if these trials are successful, NLRP3 inhibitors may eventually become standard medical care for patients with epilepsy.

However, there is still much to be investigated before NLRP3 inhibitors are officially approved for the treatment of epilepsy.

Table 1. NLRP3 inhibitors as potential epilepsy therapeutics at pre-clinical stages.

Compound	Nature of inhibitor	Mechanism of action	Disease model	References
MCC950	Sulfonylurea	Directly interacts with Walker B motif of the NACHT domain, changes NLRP3 conformation.	<i>In vitro</i> SH-SY5Y model and in vivo model of cerebral trauma induced by PTZ	[72,73,84,125,126,130,136]
		Blocks NLRP3-dependent ASC oligomerization and NLRP3 inflammasome activation	Pilocarpine-induced SE mice KA-induced SE mice	
		Blocks ATPase activity		
CY-09	Glitazones	Directly binds to Cys172 residue in the Walker A motif of NLRP3 NACHT domain and inhibits	0.83 mg/kg LPS-induced mice PTZ induced kindling mouse model	[143,145,147,216]

Glyburide	Sulfonylurea	NLRP3 ATPase activity Suppresses K _{ATP} channels and inhibition of ASC agglomeration Blocks the assembly and activation of NLRP3 inflammasome and IL-1 β release by dampening the binding of NEK7 to NLRP3	Pilocarpine-induced [150,155,156] mouse model of SE Seizures induced by i.v. or i.p. PTZ models
BHB	Natural products	Inhibition of K ⁺ efflux and reduced ASC oligomerization and speck formation Inhibit NLRP3 inflammasome activation by modulating the production of ROS and by reducing the levels of ATP in the cell.	Epileptic Kcna1-null [162–164] mice 6-Hz induced seizure model of refractory epilepsy
Amentoflavone	Naturally occurring bioflavonoid	Exerts neuroprotective effects by inhibiting the NLRP3 inflammasome	The chronic [78] epilepsy model and BV2 microglial cellular inflammation model were established by PTZ kindling or LPS stimulation, respectively.
Semaglutide	Glucagon like peptide-1	Decreases seizure severity, alleviated hippocampal neuronal apoptosis, ameliorated cognitive dysfunction by blocked ASC oligomerization and NLRP3 inflammasome activation	PTZ-kindled [74] C57/BL6J mouse model and LPS induced inflammation in BV2 cells
Huperzine A	Naturally occurring sesquiterpene	Inhibits activation of NLRP3 inflammasome in a	Rat KA-induced [173] model of epilepsy

		ROS-dependent manner		
Furosemide	Sulfonamide	Increases the efficacy of valproic acid by inhibiting NLRP3 inflammasome activation	KA-induced epileptic rats	[174]
Ibuprofen	nonsteroidal anti-inflammatory drug (NSAID)	Exhibits antiepileptic and neuroprotective effects via inhibiting NLRP3 inflammasome activation	Rat model of PTZ-induced epilepsy	[175]
Rapamycin	Macrolide compound	Inhibits NLRP3inflammasome and ROS production	PTZ-kindled rats	[176]
Chaihu-Longgu-Muli decoction	Traditional Chinese medicine	Could significantly suppress the frequency and duration time of epileptic seizures via reducing the expression of NLRP3, Caspase-1 TNF- α and IL-1 β .	Rats with TLE	[177]
Parthenolide	Naturally occurring sesquiterpene lactone	Supresses NLRP3 ATPase activity by alkylating cysteine residues in ATPase domain of NLRP3	<i>In vitro</i> LPS and ATP induced NLRP3 stimulation	[179]
Bay 11-7082	Sulfone	Inhibits protease activity of caspase 1 Blocks ATPase activity of NLRP3 (Juliana et al., 2010)	<i>In vitro</i> LPS and ATP induced NLRP3 stimulation	[179]
Oridonin	Natural terpenoids	Binds to Cys279 of NLRP3 NACHT domain and inhibits the interaction between NLRP3 and NEK7 thereby inhibiting the NLRP3 inflammasome activation	TBI mice	[178,217]
Curcumin	Natural polyphenolic compound	Inhibit IL-1b release and prevent inflammation via inhibition of NLRP3	KA-induced epileptic syndrome in Sprague Dawley rats	[68,186]

MCC950, 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea; NACHT, NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator), HET-E

(incompatibility locus protein from *Podospira anserina*) and TP1 (telomerase-associated protein); NLRP3, NLR family pyrin domain containing 3; ASC, apoptosis-associated speck-like protein containing a CARD; PTZ, pentylentetrazol; kA, kainic acid; TLE, Temporal lobe epilepsy; SE, status epilepticus, LPS, lipopolysaccharide; CY-09, 4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl) phenyl] methyl] -5-thiazolidinylidene] methyl] benzoic acid; NEK7, NIMA related kinase 7; BHB, beta-hydroxybutyrate; NSAID, nonsteroidal anti-inflammatory drug; ROS, reactive oxygen species; TBI, traumatic brain injury; ATP, adenosine triphosphate; IL-1b; interleukin -1beta.

Author Contributions: Conceptualization, V.S. I.H. and M.S.; validation, I.H. P.T., R.S. M.S. and VS; investigation, V.S., I.H. and P.T.; data curation, I.H., P.T. and D.M.B., JZ; writing—original draft preparation, I.H. and D.M.B.; writing (editing and reviewing)—I.H., P.T., D.M.B., J.Z., R.S., M.S. V.S.; visualization, I.H., P.T. and V.S.; supervision, S.B. and S.K.B.; project administration, R.M. and M.S.; funding acquisition, R.M., M.S. and V.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Research Department of the Kansas City VA Medical Center (KCVAMC) and Midwest Veterans Biomedical Research Foundation (MVBRF) at KCVAMC, Kansas City, MO, 64128.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable

Acknowledgments: We would like to thank the research and development office staff for their valuable and helpful comments on this manuscript. Graphical abstracts and figures were created on Scientific Image and Illustration Software|BioRender. The authors apologize to investigators whose contributions could not be appropriately cited because of space limitations.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

ASM	Antiseizure medication
SRS	Spontaneous recurrent seizure
BBB	Blood-brain barrier
TBI	Traumatic brain injury
DAMP	Damage-associated molecular pattern
PAMP	Pathogen-associated molecular pattern
ATP	Adenosine triphosphate
HMGB1	High mobility group box1
ROS	Reactive oxygen species
CARD	Caspase-recruitment domain
ASC	Apoptosis-associated speck-like protein containing a CARD.
PRR	Pattern-recognition receptor
NBD	Nucleotide binding domain
LRR-CR	Leucine-rich-repeat-containing receptor.
AIM2	Absent-in-melanoma 2
PYD	Pyrin domain
NOD	Nucleotide-binding oligomerization domain
NLR	Nod-like receptor
NLRP	Nod-like receptor protein
NLRP3	NLR family pyrin domain containing 3.
NLRC4	NLR family CARD domain-containing protein 4
CNS	Central nervous system
NACHT	NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator),
	HET-E (incompatibility locus protein from <i>Podospira anserina</i>) and TP1 (telomerase-associated protein).
HD	Helical domain

WHD	Winged helix domain
NIMA	Never in mitosis A
NEK7	NIMA related kinase 7
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
EM	Electron microscopy
IL	Interleukin
LPS	Lipopolysaccharide
miRNA	MicroRNA
P2RX7	P2X purinoceptor 7
ERS	Endoplasmic reticulum stress
GSDMD	Gasdermin D
TLR	Toll-like receptors
TRIF	TIR-domain-containing adapter-inducing interferon-β
RIPK1	Receptor-interacting serine/threonine-protein kinase 1
FADD	Fas-associated protein with death domain
KA	Kainic acid
TLE	Temporal lobe epilepsy
SE	Status epilepticus
PTZ	Pentylentetrazol
GABA	γ-aminobutyric acid
CAPS	Cryopyrin-associated periodic syndromes.
MCC9501-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea	
BMDM	Bone marrow-derived macrophage
HMDM	Human monocyte derived macrophage
CY-09	4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl) phenyl] methyl] -5-thiazolidinylidene] methyl] benzoic acid
FDA	Food and drug administration
BHB	Beta-hydroxybutyrate
STAT3	Signal transducer and activator of transcription 3

References

1. Loscher, W.; Klitgaard, H.; Twyman, R.E.; Schmidt, D. New avenues for anti-epileptic drug discovery and development. *Nat Rev Drug Discov* **2013**, *12*, 757-776, doi:10.1038/nrd4126.
2. Lukawski, K.; Gryta, P.; Luszczki, J.; Czuczwar, S.J. Exploring the latest avenues for antiepileptic drug discovery and development. *Expert Opin Drug Discov* **2016**, *11*, 369-382, doi:10.1517/17460441.2016.1154840.
3. Hong, Y.; Wei, C.; Fu, M.; Li, X.; Zhang, H.; Yao, B. MCC950 alleviates seizure severity and angiogenesis by inhibiting NLRP3/ IL-1β signaling pathway-mediated pyroptosis in mouse model of epilepsy. *Int Immunopharmacol* **2024**, *126*, 111236, doi:10.1016/j.intimp.2023.111236.
4. Modglin, L. Epilepsy statistics 2022. *Epilepsy statistics 2022* **2022**.
5. Guiard, B.P.; Di Giovanni, G. Central serotonin-2A (5-HT_{2A}) receptor dysfunction in depression and epilepsy: the missing link? *Front Pharmacol* **2015**, *6*, 46, doi:10.3389/fphar.2015.00046.
6. Henning, O.; Medalen, T.E.M.; Nakken, K.O.; Lossius, M.I. How often do doctors discuss drug withdrawal with their seizure-free patients with epilepsy? *Epilepsy Behav* **2020**, *108*, 107095, doi:10.1016/j.yebeh.2020.107095.
7. Loscher, W.; Klein, P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. *CNS Drugs* **2021**, *35*, 935-963, doi:10.1007/s40263-021-00827-8.
8. Lerche, H. Drug-resistant epilepsy - time to target mechanisms. *Nat Rev Neurol* **2020**, *16*, 595-596, doi:10.1038/s41582-020-00419-y.
9. Alyu, F.; Dikmen, M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. *Acta Neuropsychiatr* **2017**, *29*, 1-16, doi:10.1017/neu.2016.47.
10. Goldberg, E.M.; Coulter, D.A. Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. *Nat Rev Neurosci* **2013**, *14*, 337-349, doi:10.1038/nrn3482.
11. Sung, P.S.; Lin, P.Y.; Liu, C.H.; Su, H.C.; Tsai, K.J. Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches. *Int J Mol Sci* **2020**, *21*, doi:10.3390/ijms21030701.

12. Fuster-Matanzo, A.; Llorens-Martin, M.; Hernandez, F.; Avila, J. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. *Mediators Inflamm* **2013**, 2013, 260925, doi:10.1155/2013/260925.
13. Yong, H.Y.F.; Rawji, K.S.; Ghorbani, S.; Xue, M.; Yong, V.W. The benefits of neuroinflammation for the repair of the injured central nervous system. *Cell Mol Immunol* **2019**, 16, 540-546, doi:10.1038/s41423-019-0223-3.
14. Zhou, Q.; Lin, L.; Li, H.; Wang, H.; Jiang, S.; Huang, P.; Lin, Q.; Chen, X.; Deng, Y. Melatonin Reduces Neuroinflammation and Improves Axonal Hypomyelination by Modulating M1/M2 Microglia Polarization via JAK2-STAT3-Telomerase Pathway in Postnatal Rats Exposed to Lipopolysaccharide. *Mol Neurobiol* **2021**, 58, 6552-6576, doi:10.1007/s12035-021-02568-7.
15. Bollaerts, I.; Van Houcke, J.; Andries, L.; De Groef, L.; Moons, L. Neuroinflammation as Fuel for Axonal Regeneration in the Injured Vertebrate Central Nervous System. *Mediators Inflamm* **2017**, 2017, 9478542, doi:10.1155/2017/9478542.
16. Shi, Y.; Wei, B.; Li, L.; Wang, B.; Sun, M. Th17 cells and inflammation in neurological disorders: Possible mechanisms of action. *Front Immunol* **2022**, 13, 932152, doi:10.3389/fimmu.2022.932152.
17. Soltani Khaboushan, A.; Yazdanpanah, N.; Rezaei, N. Neuroinflammation and Proinflammatory Cytokines in Epileptogenesis. *Mol Neurobiol* **2022**, 59, 1724-1743, doi:10.1007/s12035-022-02725-6.
18. Vezzani, A.; Balosso, S.; Ravizza, T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. *Nat Rev Neurol* **2019**, 15, 459-472, doi:10.1038/s41582-019-0217-x.
19. Rana, A.; Musto, A.E. The role of inflammation in the development of epilepsy. *J Neuroinflammation* **2018**, 15, 144, doi:10.1186/s12974-018-1192-7.
20. Mahfoz, A.M.; Shahzad, N. Neuroinflammation impact in epileptogenesis and new treatment strategy. *Behav Pharmacol* **2019**, 30, 661-675, doi:10.1097/FBP.0000000000000513.
21. Banjara, M.; Ghosh, C. Sterile Neuroinflammation and Strategies for Therapeutic Intervention. *Int J Inflamm* **2017**, 2017, 8385961, doi:10.1155/2017/8385961.
22. Relja, B.; Land, W.G. Damage-associated molecular patterns in trauma. *Eur J Trauma Emerg Surg* **2020**, 46, 751-775, doi:10.1007/s00068-019-01235-w.
23. Gong, T.; Liu, L.; Jiang, W.; Zhou, R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. *Nat Rev Immunol* **2020**, 20, 95-112, doi:10.1038/s41577-019-0215-7.
24. Fleshner, M.; Frank, M.; Maier, S.F. Danger Signals and Inflammasomes: Stress-Evoked Sterile Inflammation in Mood Disorders. *Neuropsychopharmacology* **2017**, 42, 36-45, doi:10.1038/npp.2016.125.
25. Martinon, F.; Burns, K.; Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell* **2002**, 10, 417-426, doi:10.1016/s1097-2765(02)00599-3.
26. von Moltke, J.; Ayres, J.S.; Kofoed, E.M.; Chavarria-Smith, J.; Vance, R.E. Recognition of bacteria by inflammasomes. *Annu Rev Immunol* **2013**, 31, 73-106, doi:10.1146/annurev-immunol-032712-095944.
27. Hoffmann, S.; Beyer, C. A Fatal Alliance between Microglia, Inflammasomes, and Central Pain. *Int J Mol Sci* **2020**, 21, doi:10.3390/ijms21113764.
28. Trendelenburg, G. Acute neurodegeneration and the inflammasome: central processor for danger signals and the inflammatory response? *J Cereb Blood Flow Metab* **2008**, 28, 867-881, doi:10.1038/sj.jcbfm.9600609.
29. Mortezaee, K.; Khanlarkhani, N.; Beyer, C.; Zendedel, A. Inflammasome: Its role in traumatic brain and spinal cord injury. *J Cell Physiol* **2018**, 233, 5160-5169, doi:10.1002/jcp.26287.
30. Slowik, A.; Lammerding, L.; Hoffmann, S.; Beyer, C. Brain inflammasomes in stroke and depressive disorders: Regulation by oestrogen. *J Neuroendocrinol* **2018**, 30, doi:10.1111/jne.12482.
31. Walsh, J.G.; Muruve, D.A.; Power, C. Inflammasomes in the CNS. *Nat Rev Neurosci* **2014**, 15, 84-97, doi:10.1038/nrn3638.
32. Yap, J.K.Y.; Pickard, B.S.; Chan, E.W.L.; Gan, S.Y. The Role of Neuronal NLRP1 Inflammasome in Alzheimer's Disease: Bringing Neurons into the Neuroinflammation Game. *Mol Neurobiol* **2019**, 56, 7741-7753, doi:10.1007/s12035-019-1638-7.
33. Tan, C.C.; Zhang, J.G.; Tan, M.S.; Chen, H.; Meng, D.W.; Jiang, T.; Meng, X.F.; Li, Y.; Sun, Z.; Li, M.M.; et al. NLRP1 inflammasome is activated in patients with medial temporal lobe epilepsy and contributes to neuronal pyroptosis in amygdala kindling-induced rat model. *J Neuroinflammation* **2015**, 12, 18, doi:10.1186/s12974-014-0233-0.
34. de Rivero Vaccari, J.P.; Lotocki, G.; Alonso, O.F.; Bramlett, H.M.; Dietrich, W.D.; Keane, R.W. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. *J Cereb Blood Flow Metab* **2009**, 29, 1251-1261, doi:10.1038/jcbfm.2009.46.
35. de Rivero Vaccari, J.P.; Dietrich, W.D.; Keane, R.W. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. *J Cereb Blood Flow Metab* **2014**, 34, 369-375, doi:10.1038/jcbfm.2013.227.

36. Minkiewicz, J.; de Rivero Vaccari, J.P.; Keane, R.W. Human astrocytes express a novel NLRP2 inflammasome. *Glia* **2013**, *61*, 1113-1121, doi:10.1002/glia.22499.
37. Ducza, L.; Szucs, P.; Hegedus, K.; Bakk, E.; Gajtko, A.; Weber, I.; Hollo, K. NLRP2 Is Overexpressed in Spinal Astrocytes at the Peak of Mechanical Pain Sensitivity during Complete Freund Adjuvant-Induced Persistent Pain. *Int J Mol Sci* **2021**, *22*, doi:10.3390/ijms222111408.
38. Zhang, Z.; Guo, P.; Huang, S.; Jia, Z.; Chen, T.; Liu, X.; Feng, H.; Chen, Y. Inhibiting Microglia-Derived NLRP3 Alleviates Subependymal Edema and Cognitive Dysfunction in Posthemorrhagic Hydrocephalus after Intracerebral Hemorrhage via AMPK/Beclin-1 Pathway. *Oxid Med Cell Longev* **2022**, *2022*, 4177317, doi:10.1155/2022/4177317.
39. Shi, F.; Yang, Y.; Kouadir, M.; Fu, Y.; Yang, L.; Zhou, X.; Yin, X.; Zhao, D. Inhibition of phagocytosis and lysosomal acidification suppresses neurotoxic prion peptide-induced NALP3 inflammasome activation in BV2 microglia. *J Neuroimmunol* **2013**, *260*, 121-125, doi:10.1016/j.jneuroim.2013.04.016.
40. Hanslik, K.L.; Ulland, T.K. The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease. *Front Neurol* **2020**, *11*, 570711, doi:10.3389/fneur.2020.570711.
41. Gustin, A.; Kirchmeyer, M.; Koncina, E.; Felten, P.; Losciuto, S.; Heurtaux, T.; Tardivel, A.; Heuschling, P.; Dostert, C. NLRP3 Inflammasome Is Expressed and Functional in Mouse Brain Microglia but Not in Astrocytes. *PLoS One* **2015**, *10*, e0130624, doi:10.1371/journal.pone.0130624.
42. Lim, J.; Kim, M.J.; Park, Y.; Ahn, J.W.; Hwang, S.J.; Moon, J.S.; Cho, K.G.; Kwack, K. Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients. *Sci Rep* **2019**, *9*, 7895, doi:10.1038/s41598-019-44261-9.
43. Freeman, L.; Guo, H.; David, C.N.; Brickey, W.J.; Jha, S.; Ting, J.P. NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. *J Exp Med* **2017**, *214*, 1351-1370, doi:10.1084/jem.20150237.
44. Wu, P.J.; Liu, H.Y.; Huang, T.N.; Hsueh, Y.P. AIM 2 inflammasomes regulate neuronal morphology and influence anxiety and memory in mice. *Sci Rep* **2016**, *6*, 32405, doi:10.1038/srep32405.
45. Adamczak, S.E.; de Rivero Vaccari, J.P.; Dale, G.; Brand, F.J., 3rd; Nonner, D.; Bullock, M.R.; Dahl, G.P.; Dietrich, W.D.; Keane, R.W. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. *J Cereb Blood Flow Metab* **2014**, *34*, 621-629, doi:10.1038/jcbfm.2013.236.
46. Sharif, H.; Wang, L.; Wang, W.L.; Magupalli, V.G.; Andreeva, L.; Qiao, Q.; Hauenstein, A.V.; Wu, Z.; Nunez, G.; Mao, Y.; et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. *Nature* **2019**, *570*, 338-343, doi:10.1038/s41586-019-1295-z.
47. He, Y.; Zeng, M.Y.; Yang, D.; Motro, B.; Nunez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. *Nature* **2016**, *530*, 354-357, doi:10.1038/nature16959.
48. Shi, H.; Wang, Y.; Li, X.; Zhan, X.; Tang, M.; Fina, M.; Su, L.; Pratt, D.; Bu, C.H.; Hildebrand, S.; et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. *Nat Immunol* **2016**, *17*, 250-258, doi:10.1038/ni.3333.
49. Liu, G.; Chen, X.; Wang, Q.; Yuan, L. NEK7: a potential therapy target for NLRP3-related diseases. *Biosci Trends* **2020**, *14*, 74-82, doi:10.5582/bst.2020.01029.
50. Xu, J.; Lu, L.; Li, L. NEK7: a novel promising therapy target for NLRP3-related inflammatory diseases. *Acta Biochim Biophys Sin (Shanghai)* **2016**, *48*, 966-968, doi:10.1093/abbs/gmw080.
51. El-Sharkawy, L.Y.; Brough, D.; Freeman, S. Inhibiting the NLRP3 Inflammasome. *Molecules* **2020**, *25*, doi:10.3390/molecules25235533.
52. Mangan, M.S.J.; Olhava, E.J.; Roush, W.R.; Seidel, H.M.; Glick, G.D.; Latz, E. Targeting the NLRP3 inflammasome in inflammatory diseases. *Nat Rev Drug Discov* **2018**, *17*, 588-606, doi:10.1038/nrd.2018.97.
53. Bauernfeind, F.G.; Horvath, G.; Stutz, A.; Alnemri, E.S.; MacDonald, K.; Speert, D.; Fernandes-Alnemri, T.; Wu, J.; Monks, B.G.; Fitzgerald, K.A.; et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. *J Immunol* **2009**, *183*, 787-791, doi:10.4049/jimmunol.0901363.
54. Wei, M.; Wang, L.; Wu, T.; Xi, J.; Han, Y.; Yang, X.; Zhang, D.; Fang, Q.; Tang, B. NLRP3 Activation Was Regulated by DNA Methylation Modification during Mycobacterium tuberculosis Infection. *Biomed Res Int* **2016**, *2016*, 4323281, doi:10.1155/2016/4323281.
55. Haneklaus, M.; O'Neil, J.D.; Clark, A.R.; Masters, S.L.; O'Neill, L.A.J. The RNA-binding protein Tristetraprolin (TTP) is a critical negative regulator of the NLRP3 inflammasome. *J Biol Chem* **2017**, *292*, 6869-6881, doi:10.1074/jbc.M116.772947.
56. Bauernfeind, F.; Rieger, A.; Schildberg, F.A.; Knolle, P.A.; Schmid-Burgk, J.L.; Hornung, V. NLRP3 inflammasome activity is negatively controlled by miR-223. *J Immunol* **2012**, *189*, 4175-4181, doi:10.4049/jimmunol.1201516.
57. Seok, J.K.; Kang, H.C.; Cho, Y.Y.; Lee, H.S.; Lee, J.Y. Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules. *Front Immunol* **2020**, *11*, 618231, doi:10.3389/fimmu.2020.618231.

58. Schroder, K.; Zhou, R.; Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? *Science* **2010**, *327*, 296-300, doi:10.1126/science.1184003.
59. de Vasconcelos, N.M.; Lamkanfi, M. Recent Insights on Inflammasomes, Gasdermin Pores, and Pyroptosis. *Cold Spring Harb Perspect Biol* **2020**, *12*, doi:10.1101/cshperspect.a036392.
60. Fernandes-Alnemri, T.; Wu, J.; Yu, J.W.; Datta, P.; Miller, B.; Jankowski, W.; Rosenberg, S.; Zhang, J.; Alnemri, E.S. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. *Cell Death Differ* **2007**, *14*, 1590-1604, doi:10.1038/sj.cdd.4402194.
61. Kayagaki, N.; Stowe, I.B.; Lee, B.L.; O'Rourke, K.; Anderson, K.; Warming, S.; Cuellar, T.; Haley, B.; Roose-Girma, M.; Phung, Q.T.; et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* **2015**, *526*, 666-671, doi:10.1038/nature15541.
62. Yi, Y.S. Caspase-11 Non-Canonical Inflammasome: Emerging Activator and Regulator of Infection-Mediated Inflammatory Responses. *Int J Mol Sci* **2020**, *21*, doi:10.3390/ijms21082736.
63. Vigano, E.; Diamond, C.E.; Spreafico, R.; Balachander, A.; Sobota, R.M.; Mortellaro, A. Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes. *Nat Commun* **2015**, *6*, 8761, doi:10.1038/ncomms9761.
64. Santos, J.C.; Dick, M.S.; Lagrange, B.; Degrandi, D.; Pfeffer, K.; Yamamoto, M.; Meunier, E.; Pelczar, P.; Henry, T.; Broz, P. LPS targets host guanylate-binding proteins to the bacterial outer membrane for non-canonical inflammasome activation. *EMBO J* **2018**, *37*, doi:10.15252/embj.201798089.
65. Gaidt, M.M.; Ebert, T.S.; Chauhan, D.; Schmidt, T.; Schmid-Burgk, J.L.; Rapino, F.; Robertson, A.A.; Cooper, M.A.; Graf, T.; Hornung, V. Human Monocytes Engage an Alternative Inflammasome Pathway. *Immunity* **2016**, *44*, 833-846, doi:10.1016/j.immuni.2016.01.012.
66. Gurung, P.; Kanneganti, T.D. Novel roles for caspase-8 in IL-1 β and inflammasome regulation. *Am J Pathol* **2015**, *185*, 17-25, doi:10.1016/j.ajpath.2014.08.025.
67. Yang, Y.; Wang, H.; Kouadir, M.; Song, H.; Shi, F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. *Cell Death Dis* **2019**, *10*, 128, doi:10.1038/s41419-019-1413-8.
68. He, Q.; Jiang, L.; Man, S.; Wu, L.; Hu, Y.; Chen, W. Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model. *Curr Neurovasc Res* **2018**, *15*, 186-192, doi:10.2174/1567202615666180731100224.
69. Lin, W.S.; Hsu, T.R. Hypothesis: Febrile infection-related epilepsy syndrome is a microglial NLRP3 inflammasome/IL-1 axis-driven autoinflammatory syndrome. *Clin Transl Immunology* **2021**, *10*, e1299, doi:10.1002/cti2.1299.
70. Meng, X.F.; Tan, L.; Tan, M.S.; Jiang, T.; Tan, C.C.; Li, M.M.; Wang, H.F.; Yu, J.T. Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus. *J Neuroinflammation* **2014**, *11*, 212, doi:10.1186/s12974-014-0212-5.
71. Xiang, T.; Luo, X.; Ye, L.; Huang, H.; Wu, Y. Klotho alleviates NLRP3 inflammasome-mediated neuroinflammation in a temporal lobe epilepsy rat model by activating the Nrf2 signaling pathway. *Epilepsy Behav* **2022**, *128*, 108509, doi:10.1016/j.yebeh.2021.108509.
72. Shen, K.; Mao, Q.; Yin, X.; Zhang, C.; Jin, Y.; Deng, A.; Gu, Z.; Chen, B. NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis. *Curr Neurovasc Res* **2018**, *15*, 276-281, doi:10.2174/1567202616666181122165540.
73. Yue, J.; Wei, Y.J.; Yang, X.L.; Liu, S.Y.; Yang, H.; Zhang, C.Q. NLRP3 inflammasome and endoplasmic reticulum stress in the epileptogenic zone in temporal lobe epilepsy: molecular insights into their interdependence. *Neuropathol Appl Neurobiol* **2020**, *46*, 770-785, doi:10.1111/nan.12621.
74. Wang, L.; Ding, J.; Zhu, C.; Guo, B.; Yang, W.; He, W.; Li, X.; Wang, Y.; Li, W.; Wang, F.; et al. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazolekindled mice. *Int J Mol Med* **2021**, *48*, doi:10.3892/ijmm.2021.5052.
75. Wang, Z.; Zhou, L.; An, D.; Xu, W.; Wu, C.; Sha, S.; Li, Y.; Zhu, Y.; Chen, A.; Du, Y.; et al. TRPV4-induced inflammatory response is involved in neuronal death in pilocarpine model of temporal lobe epilepsy in mice. *Cell Death Dis* **2019**, *10*, 386, doi:10.1038/s41419-019-1612-3.
76. Magalhaes, D.M.; Pereira, N.; Rombo, D.M.; Beltrao-Cavacas, C.; Sebastiao, A.M.; Valente, C.A. Ex vivo model of epilepsy in organotypic slices-a new tool for drug screening. *J Neuroinflammation* **2018**, *15*, 203, doi:10.1186/s12974-018-1225-2.
77. Jiang, Q.; Tang, G.; Zhong, X.M.; Ding, D.R.; Wang, H.; Li, J.N. Role of Stat3 in NLRP3/caspase-1-mediated hippocampal neuronal pyroptosis in epileptic mice. *Synapse* **2021**, *75*, e22221, doi:10.1002/syn.22221.
78. Rong, S.; Wan, D.; Fan, Y.; Liu, S.; Sun, K.; Huo, J.; Zhang, P.; Li, X.; Xie, X.; Wang, F.; et al. Amentoflavone Affects Epileptogenesis and Exerts Neuroprotective Effects by Inhibiting NLRP3 Inflammasome. *Front Pharmacol* **2019**, *10*, 856, doi:10.3389/fphar.2019.00856.
79. Yue, J.; He, J.; Wei, Y.; Shen, K.; Wu, K.; Yang, X.; Liu, S.; Zhang, C.; Yang, H. Decreased expression of Rev-Erb α in the epileptic foci of temporal lobe epilepsy and activation of Rev-Erb α have anti-

- inflammatory and neuroprotective effects in the pilocarpine model. *J Neuroinflammation* **2020**, *17*, 43, doi:10.1186/s12974-020-1718-7.
80. Wu C, Z.G., Chen L, Kim S, Yu J, Hu G, Chen J, Huang Y, Zheng G, Huang S. The Role of NLRP3 and IL-1 β in Refractory Epilepsy Brain Injury. *Front Neurol.* **2020**, *10*, 1418, doi:10.3389/fneur.2019.01418.
 81. Cristina de Brito Toscano, E.; Leandro Marciano Vieira, E.; Boni Rocha Dias, B.; Vidigal Caliari, M.; Paula Goncalves, A.; Varela Giannetti, A.; Mauricio Siqueira, J.; Kimie Suemoto, C.; Elaine Paraizo Leite, R.; Nitrini, R.; et al. NLRP3 and NLRP1 inflammasomes are up-regulated in patients with mesial temporal lobe epilepsy and may contribute to overexpression of caspase-1 and IL-beta in sclerotic hippocampi. *Brain Res* **2021**, *1752*, 147230, doi:10.1016/j.brainres.2020.147230.
 82. Wu, J., Chen, L., Wang, S., Li, Y., Liu, L., Chen, G., Wang, S. and Zhou, S. Negative Regulation of Autophagy in Activating Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasomes in the Hippocampus of an Epilepsy Rat Model. *Nanosci. Nanotechnol. Lett.* **2019**, *11*, 947-959, doi:https://doi.org/10.1166/nnl.2019.2958.
 83. Liu, Z.; Xian, H.; Ye, X.; Chen, J.; Ma, Y.; Huang, W. Increased levels of NLRP3 in children with febrile seizures. *Brain Dev* **2020**, *42*, 336-341, doi:10.1016/j.braindev.2019.12.013.
 84. Zhang, H.; Yu, S.; Xia, L.; Peng, X.; Wang, S.; Yao, B. NLRP3 Inflammasome Activation Enhances ADK Expression to Accelerate Epilepsy in Mice. *Neurochem Res* **2022**, *47*, 713-722, doi:10.1007/s11064-021-03479-8.
 85. Pohlentz, M.S.; Muller, P.; Cases-Cunillera, S.; Opitz, T.; Surges, R.; Hamed, M.; Vatter, H.; Schoch, S.; Becker, A.J.; Pitsch, J. Characterisation of NLRP3 pathway-related neuroinflammation in temporal lobe epilepsy. *PLoS One* **2022**, *17*, e0271995, doi:10.1371/journal.pone.0271995.
 86. Dixit, A.B.; Banerjee, J.; Srivastava, A.; Tripathi, M.; Sarkar, C.; Kakkar, A.; Jain, M.; Chandra, P.S. RNA-seq analysis of hippocampal tissues reveals novel candidate genes for drug refractory epilepsy in patients with MTLE-HS. *Genomics* **2016**, *107*, 178-188, doi:10.1016/j.ygeno.2016.04.001.
 87. Gao, B.; Wu, Y.; Yang, Y.J.; Li, W.Z.; Dong, K.; Zhou, J.; Yin, Y.Y.; Huang, D.K.; Wu, W.N. Sinomenine exerts anticonvulsant profile and neuroprotective activity in pentylenetetrazole kindled rats: involvement of inhibition of NLRP1 inflammasome. *J Neuroinflammation* **2018**, *15*, 152, doi:10.1186/s12974-018-1199-0.
 88. Samadianzakaria, A., Abdolmaleki, Z., Faedmalekia, F. The effect of valproic acid and furosemide on the regulation of the inflammasome complex (NLRP1 and NLRP3 mRNA) in the brain of epileptic animal model. *Brain Research Bulletin* **2022**, *191*, 20-29, doi:https://doi.org/10.1016/j.brainresbull.2022.10.002.
 89. Cosford, N.D.; Meinke, P.T.; Stauderman, K.A.; Hess, S.D. Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy. *Curr Drug Targets CNS Neurol Disord* **2002**, *1*, 81-104, doi:10.2174/1568007023339463.
 90. Sills, G.J.; Rogawski, M.A. Mechanisms of action of currently used antiseizure drugs. *Neuropharmacology* **2020**, *168*, 107966, doi:10.1016/j.neuropharm.2020.107966.
 91. Treiman, D.M. GABAergic mechanisms in epilepsy. *Epilepsia* **2001**, *42 Suppl 3*, 8-12, doi:10.1046/j.1528-1157.2001.042suppl.3008.x.
 92. Romoli, M.; Mazzocchi, P.; D'Alonzo, R.; Siligini, S.; Rinaldi, V.E.; Verrotti, A.; Calabresi, P.; Costa, C. Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. *Curr Neuropharmacol* **2019**, *17*, 926-946, doi:10.2174/1570159X17666181227165722.
 93. Johannessen, C.U.; Johannessen, S.I. Valproate: past, present, and future. *CNS Drug Rev* **2003**, *9*, 199-216, doi:10.1111/j.1527-3458.2003.tb00249.x.
 94. Glauser, T.A.; Cnaan, A.; Shinnar, S.; Hirtz, D.G.; Dlugos, D.; Masur, D.; Clark, P.O.; Adamson, P.C.; Childhood Absence Epilepsy Study, T. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. *Epilepsia* **2013**, *54*, 141-155, doi:10.1111/epi.12028.
 95. Brigo, F.; Igwe, S.C.; Bragazzi, N.L.; Lattanzi, S. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. *Cochrane Database Syst Rev* **2022**, *2*, CD013028, doi:10.1002/14651858.CD013028.pub3.
 96. Jenner, P.; Pratt, J.A.; Marsden, C.D. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. *Adv Neurol* **1986**, *43*, 629-643.
 97. Nardou, R.; Yamamoto, S.; Chazal, G.; Bhar, A.; Ferrand, N.; Dulac, O.; Ben-Ari, Y.; Khalilov, I. Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital. *Brain* **2011**, *134*, 987-1002, doi:10.1093/brain/awr041.
 98. Zhang, L.L.; Zeng, L.N.; Li, Y.P. Side effects of phenobarbital in epilepsy: a systematic review. *Epileptic Disord* **2011**, *13*, 349-365, doi:10.1684/epd.2011.0444.
 99. Contreras-Garcia, I.J.; Cardenas-Rodriguez, N.; Romo-Mancillas, A.; Bandala, C.; Zamudio, S.R.; Gomez-Manzo, S.; Hernandez-Ochoa, B.; Mendoza-Torreblanca, J.G.; Pichardo-Macias, L.A. Levetiracetam Mechanisms of Action: From Molecules to Systems. *Pharmaceuticals (Basel)* **2022**, *15*, doi:10.3390/ph15040475.
 100. Itoh, K.; Ishihara, Y.; Komori, R.; Nochi, H.; Taniguchi, R.; Chiba, Y.; Ueno, M.; Takata-Tsuji, F.; Dohgu, S.; Kataoka, Y. Levetiracetam treatment influences blood-brain barrier failure associated with angiogenesis

- and inflammatory responses in the acute phase of epileptogenesis in post-status epilepticus mice. *Brain Res* **2016**, 1652, 1-13, doi:10.1016/j.brainres.2016.09.038.
101. Ebrahimi, H.A.; Ebrahimi, F. The effect of lamotrigine on epilepsy. *Iran J Neurol* **2012**, 11, 162-163.
 102. Goldsmith, D.R.; Wagstaff, A.J.; Ibbotson, T.; Perry, C.M. Lamotrigine: a review of its use in bipolar disorder. *Drugs* **2003**, 63, 2029-2050, doi:10.2165/00003495-200363190-00009.
 103. Marson, A.; Burnside, G.; Appleton, R.; Smith, D.; Leach, J.P.; Sills, G.; Tudur-Smith, C.; Plumpton, C.; Hughes, D.A.; Williamson, P.; et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. *Lancet* **2021**, 397, 1363-1374, doi:10.1016/S0140-6736(21)00247-6.
 104. Guerrini, R.; Parmeggiani, L. Topiramate and its clinical applications in epilepsy. *Expert Opin Pharmacother* **2006**, 7, 811-823, doi:10.1517/14656566.7.6.811.
 105. Davies, J.A. Mechanisms of action of antiepileptic drugs. *Seizure* **1995**, 4, 267-271, doi:10.1016/s1059-1311(95)80003-4.
 106. Huang, C.R.; Chuang, H.Y.; Chen, N.C.; Chen, S.F.; Hsu, C.Y.; Chuang, Y.C. Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy. *J Clin Med* **2021**, 10, doi:10.3390/jcm10153380.
 107. Bang, L.M.; Goa, K.L. Spotlight on oxcarbazepine in epilepsy. *CNS Drugs* **2004**, 18, 57-61, doi:10.2165/00023210-200418010-00006.
 108. Chang, X.C.; Yuan, H.; Wang, Y.; Xu, H.Q.; Hong, W.K.; Zheng, R.Y. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. *Cochrane Database Syst Rev* **2017**, 10, CD008907, doi:10.1002/14651858.CD008907.pub3.
 109. Landmark, C.J.; Rektorli, L.; Burns, M.L.; Revdal, E.; Johannessen, S.I.; Brodtkorb, E. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. *Epileptic Disord* **2021**, 23, 426-431, doi:10.1684/epd.2021.1273.
 110. D'Andrea Meira, I.; Romao, T.T.; Pires do Prado, H.J.; Kruger, L.T.; Pires, M.E.P.; da Conceicao, P.O. Ketogenic Diet and Epilepsy: What We Know So Far. *Front Neurosci* **2019**, 13, 5, doi:10.3389/fnins.2019.00005.
 111. Gonzalez, H.F.J.; Yengo-Kahn, A.; Englot, D.J. Vagus Nerve Stimulation for the Treatment of Epilepsy. *Neurosurg Clin N Am* **2019**, 30, 219-230, doi:10.1016/j.nec.2018.12.005.
 112. Ohemeng, K.K.; Parham, K. Vagal Nerve Stimulation: Indications, Implantation, and Outcomes. *Otolaryngol Clin North Am* **2020**, 53, 127-143, doi:10.1016/j.otc.2019.09.008.
 113. Wallace, S.J. Newer antiepileptic drugs: advantages and disadvantages. *Brain Dev* **2001**, 23, 277-283, doi:10.1016/s0387-7604(01)00230-3.
 114. Farhat, G.; Yamout, B.; Mikati, M.A.; Demirjian, S.; Sawaya, R.; El-Hajj Fuleihan, G. Effect of antiepileptic drugs on bone density in ambulatory patients. *Neurology* **2002**, 58, 1348-1353, doi:10.1212/wnl.58.9.1348.
 115. Paulson, O.B.; Gyory, A.; Hertz, M.M. Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs. *Clin Pharmacol Ther* **1982**, 32, 466-477, doi:10.1038/clpt.1982.190.
 116. Lin, T.Y.; Hung, C.Y.; Chiu, K.M.; Lee, M.Y.; Lu, C.W.; Wang, S.J. Neferine, an Alkaloid from Lotus Seed Embryos, Exerts Antiseizure and Neuroprotective Effects in a Kainic Acid-Induced Seizure Model in Rats. *Int J Mol Sci* **2022**, 23, doi:10.3390/ijms23084130.
 117. Han, X.; Sun, S.; Sun, Y.; Song, Q.; Zhu, J.; Song, N.; Chen, M.; Sun, T.; Xia, M.; Ding, J.; et al. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. *Autophagy* **2019**, 15, 1860-1881, doi:10.1080/15548627.2019.1596481.
 118. Sharma, B.; Satija, G.; Madan, A.; Garg, M.; Alam, M.M.; Shaquiquzzaman, M.; Khanna, S.; Tiwari, P.; Parvez, S.; Iqbal, A.; et al. Role of NLRP3 Inflammasome and Its Inhibitors as Emerging Therapeutic Drug Candidate for Alzheimer's Disease: a Review of Mechanism of Activation, Regulation, and Inhibition. *Inflammation* **2022**, 1-32, doi:10.1007/s10753-022-01730-0.
 119. Tezcan, G.; Garanina, E.E.; Alsaadi, M.; Gilazieva, Z.E.; Martinova, E.V.; Markelova, M.I.; Arkhipova, S.S.; Hamza, S.; McIntyre, A.; Rizvanov, A.A.; et al. Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer. *Front Immunol* **2020**, 11, 607881, doi:10.3389/fimmu.2020.607881.
 120. Wu, A.G.; Zhou, X.G.; Qiao, G.; Yu, L.; Tang, Y.; Yan, L.; Qiu, W.Q.; Pan, R.; Yu, C.L.; Law, B.Y.; et al. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. *Ageing Res Rev* **2021**, 65, 101202, doi:10.1016/j.arr.2020.101202.
 121. Chen, Q.L.; Yin, H.R.; He, Q.Y.; Wang, Y. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. *Biomed Pharmacother* **2021**, 138, 111442, doi:10.1016/j.biopha.2021.111442.
 122. Coll, R.C.; Schroder, K.; Pelegrin, P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. *Trends Pharmacol Sci* **2022**, 43, 653-668, doi:10.1016/j.tips.2022.04.003.
 123. Schwaid, A.G.; Spencer, K.B. Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space. *J Med Chem* **2021**, 64, 101-122, doi:10.1021/acs.jmedchem.0c01307.

124. Coll, R.C.; Robertson, A.A.; Chae, J.J.; Higgins, S.C.; Munoz-Planillo, R.; Inserra, M.C.; Vetter, I.; Dungan, L.S.; Monks, B.G.; Stutz, A.; et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. *Nat Med* **2015**, *21*, 248-255, doi:10.1038/nm.3806.
125. Coll, R.C.; Hill, J.R.; Day, C.J.; Zamoshnikova, A.; Boucher, D.; Massey, N.L.; Chitty, J.L.; Fraser, J.A.; Jennings, M.P.; Robertson, A.A.B.; et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. *Nat Chem Biol* **2019**, *15*, 556-559, doi:10.1038/s41589-019-0277-7.
126. Tapia-Abellan, A.; Angosto-Bazarra, D.; Martinez-Banaclocha, H.; de Torre-Minguela, C.; Ceron-Carrasco, J.P.; Perez-Sanchez, H.; Arostegui, J.I.; Pelegrin, P. MCC950 closes the active conformation of NLRP3 to an inactive state. *Nat Chem Biol* **2019**, *15*, 560-564, doi:10.1038/s41589-019-0278-6.
127. Umiker, B.; Lee, H.H.; Cope, J.; Ajami, N.J.; Laine, J.P.; Fregeau, C.; Ferguson, H.; Alves, S.E.; Sciammetta, N.; Kleinschek, M.; et al. The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice. *Innate Immun* **2019**, *25*, 132-143, doi:10.1177/1753425919826367.
128. Saber, S.; El-Kader, E.M.A. Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90/NLRP3 interaction and inducing autophagy in rats. *Inflammopharmacology* **2021**, *29*, 237-251, doi:10.1007/s10787-020-00730-6.
129. Dempsey, C.; Rubio Araiz, A.; Bryson, K.J.; Finucane, O.; Larkin, C.; Mills, E.L.; Robertson, A.A.B.; Cooper, M.A.; O'Neill, L.A.J.; Lynch, M.A. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. *Brain Behav Immun* **2017**, *61*, 306-316, doi:10.1016/j.bbi.2016.12.014.
130. Li, J.; Zhuang, L.; Luo, X.; Liang, J.; Sun, E.; He, Y. Protection of MCC950 against Alzheimer's disease via inhibiting neuronal pyroptosis in SAMP8 mice. *Exp Brain Res* **2020**, *238*, 2603-2614, doi:10.1007/s00221-020-05916-6.
131. Guo, C.; Fu, R.; Wang, S.; Huang, Y.; Li, X.; Zhou, M.; Zhao, J.; Yang, N. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. *Clin Exp Immunol* **2018**, *194*, 231-243, doi:10.1111/cei.13167.
132. Li, R.; Zhang, J.; Wang, Q.; Cheng, M.; Lin, B. TPM1 mediates inflammation downstream of TREM2 via the PKA/CREB signaling pathway. *J Neuroinflammation* **2022**, *19*, 257, doi:10.1186/s12974-022-02619-3.
133. Gao, R.; Shi, H.; Chang, S.; Gao, Y.; Li, X.; Lv, C.; Yang, H.; Xiang, H.; Yang, J.; Xu, L.; et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. *Int Immunopharmacol* **2019**, *74*, 105575, doi:10.1016/j.intimp.2019.04.022.
134. Xu, L.; Zhang, C.; He, D.; Jiang, N.; Bai, Y.; Xin, Y. Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis. *Life Sci* **2020**, *253*, 117747, doi:10.1016/j.lfs.2020.117747.
135. Zhang, X.; Xu, A.; Lv, J.; Zhang, Q.; Ran, Y.; Wei, C.; Wu, J. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. *Eur J Med Chem* **2020**, *185*, 111822, doi:10.1016/j.ejmech.2019.111822.
136. Ismael, S.; Nasoohi, S.; Ishrat, T. MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury. *J Neurotrauma* **2018**, *35*, 1294-1303, doi:10.1089/neu.2017.5344.
137. Engel, T.; Sanz-Rodriguez, A.; Jimenez-Mateos, E.M.; Concannon, C.G.; Jimenez-Pacheco, A.; Moran, C.; Mesuret, G.; Petit, E.; Delanty, N.; Farrell, M.A.; et al. CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. *Brain* **2013**, *136*, 577-592, doi:10.1093/brain/aww337.
138. Abais, J.M.; Xia, M.; Zhang, Y.; Boini, K.M.; Li, P.L. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? *Antioxid Redox Signal* **2015**, *22*, 1111-1129, doi:10.1089/ars.2014.5994.
139. Paul, R.; Choudhury, A.; Chandra Boruah, D.; Devi, R.; Bhattacharya, P.; Choudhury, M.D.; Borah, A. Hypercholesterolemia causes psychomotor abnormalities in mice and alterations in cortico-striatal biogenic amine neurotransmitters: Relevance to Parkinson's disease. *Neurochem Int* **2017**, *108*, 15-26, doi:10.1016/j.neuint.2017.01.021.
140. Zhu, X.; Dong, J.; Han, B.; Huang, R.; Zhang, A.; Xia, Z.; Chang, H.; Chao, J.; Yao, H. Neuronal Nitric Oxide Synthase Contributes to PTZ Kindling Epilepsy-Induced Hippocampal Endoplasmic Reticulum Stress and Oxidative Damage. *Front Cell Neurosci* **2017**, *11*, 377, doi:10.3389/fncel.2017.00377.
141. Mangan, M.S.J.; Olhava, E.J.; Roush, W.R.; Seidel, H.M.; Glick, G.D.; Latz, E. Targeting the NLRP3 inflammasome in inflammatory diseases. *Nat Rev Drug Discov* **2018**, *17*, 688, doi:10.1038/nrd.2018.149.
142. Jiang, H.; He, H.; Chen, Y.; Huang, W.; Cheng, J.; Ye, J.; Wang, A.; Tao, J.; Wang, C.; Liu, Q.; et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. *J Exp Med* **2017**, *214*, 3219-3238, doi:10.1084/jem.20171419.
143. Fan, Y.; Xue, G.; Chen, Q.; Lu, Y.; Dong, R.; Yuan, H. CY-09 Inhibits NLRP3 Inflammasome Activation to Relieve Pain via TRPA1. *Comput Math Methods Med* **2021**, *2021*, 9806690, doi:10.1155/2021/9806690.

144. Qiao, J.; Wu, X.; Luo, Q.; Wei, G.; Xu, M.; Wu, Y.; Liu, Y.; Li, X.; Zi, J.; Ju, W.; et al. NLRP3 regulates platelet integrin $\alpha\text{IIb}\beta\text{3}$ outside-in signaling, hemostasis and arterial thrombosis. *Haematologica* **2018**, *103*, 1568-1576, doi:10.3324/haematol.2018.191700.
145. Shen, K.; Jiang, W.; Zhang, C.; Cai, L.; Wang, Q.; Yu, H.; Tang, Z.; Gu, Z.; Chen, B. Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylentetrazole. *Curr Mol Pharmacol* **2021**, *14*, 579-586, doi:10.2174/1874467213666200810140749.
146. Zhu, Q.; Zheng, F.; You, W.; Kang, X.; Chen, C.; Pan, Z.; Zhou, J.; Hu, W. Expression of Histone H1 in Rats with Traumatic Brain Injury and the Effect of the NLRP3 Inflammasome Pathway. *World Neurosurg* **2023**, *171*, e286-e290, doi:10.1016/j.wneu.2022.12.009.
147. Wang, Y.; Liu, Y.J.; Zhang, M.M.; Zhou, H.; Gao, Y.H.; Cheng, W.J.; Ye, Z.W.; Yuan, Z.Y.; Xu, G.H.; Li, C.F.; et al. CY-09 Alleviates the Depression-like Behaviors via Inhibiting NLRP3 Inflammasome-Mediated Neuroinflammation in Lipopolysaccharide-Induced Mice. *ACS Chem Neurosci* **2022**, *13*, 3291-3302, doi:10.1021/acschemneuro.2c00348.
148. Riddle, M.C. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide? *J Clin Endocrinol Metab* **2003**, *88*, 528-530, doi:10.1210/jc.2002-021971.
149. Perregaux, D.G.; McNiff, P.; Laliberte, R.; Hawryluk, N.; Peurano, H.; Stam, E.; Eggler, J.; Griffiths, R.; Dombroski, M.A.; Gabel, C.A. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. *J Pharmacol Exp Ther* **2001**, *299*, 187-197.
150. Coelho, F.R.; Cavriani, G.; Soares, A.L.; Teixeira, S.A.; Almeida, P.C.; Sudo-Hayashi, L.S.; Muscara, M.N.; Oliveira-Filho, R.M.; Vargaftig, B.B.; Tavares-de-Lima, W. Lymphatic-borne IL-1 β and the inducible isoform of nitric oxide synthase trigger the bronchial hyporesponsiveness after intestinal ischemia/reperfusion in rats. *Shock* **2007**, *28*, 694-699, doi:10.1097/shk.0b013e318053621d.
151. Lamkanfi, M.; Mueller, J.L.; Vitari, A.C.; Misaghi, S.; Fedorova, A.; Deshayes, K.; Lee, W.P.; Hoffman, H.M.; Dixit, V.M. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. *J Cell Biol* **2009**, *187*, 61-70, doi:10.1083/jcb.200903124.
152. Masters, S.L.; Dunne, A.; Subramanian, S.L.; Hull, R.L.; Tannahill, G.M.; Sharp, F.A.; Becker, C.; Franchi, L.; Yoshihara, E.; Chen, Z.; et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 β in type 2 diabetes. *Nat Immunol* **2010**, *11*, 897-904, doi:10.1038/ni.1935.
153. Lebreton, F.; Berishvili, E.; Parnaud, G.; Rouget, C.; Bosco, D.; Berney, T.; Lavallard, V. NLRP3 inflammasome is expressed and regulated in human islets. *Cell Death Dis* **2018**, *9*, 726, doi:10.1038/s41419-018-0764-x.
154. Liu, H.; Gu, C.; Liu, M.; Liu, G.; Wang, Y. NEK7 mediated assembly and activation of NLRP3 inflammasome downstream of potassium efflux in ventilator-induced lung injury. *Biochem Pharmacol* **2020**, *177*, 113998, doi:10.1016/j.bcp.2020.113998.
155. Liu, K.; Zhu, J.; Chang, Y.; Lin, Z.; Shi, Z.; Li, X.; Chen, X.; Lin, C.; Pan, S.; Huang, K. Attenuation of cerebral edema facilitates recovery of glymphatic system function after status epilepticus. *JCI Insight* **2021**, *6*, doi:10.1172/jci.insight.151835.
156. Shafaroodi, H.; Barati, S.; Ghasemi, M.; Almasirad, A.; Moezi, L. A role for ATP-sensitive potassium channels in the anticonvulsant effects of triamterene in mice. *Epilepsy Res* **2016**, *121*, 8-13, doi:10.1016/j.eplepsyres.2016.01.003.
157. Goldberg, E.L.; Asher, J.L.; Molony, R.D.; Shaw, A.C.; Zeiss, C.J.; Wang, C.; Morozova-Roche, L.A.; Herzog, R.I.; Iwasaki, A.; Dixit, V.D. beta-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares. *Cell Rep* **2017**, *18*, 2077-2087, doi:10.1016/j.celrep.2017.02.004.
158. Jiang, Z.; Yin, X.; Wang, M.; Wang, Y.; Li, F.; Gao, Y.; Han, G.; Gao, Z.; Wang, Z. beta-Hydroxybutyrate alleviates pyroptosis in MPP(+)/MPTP-induced Parkinson's disease models via inhibiting STAT3/NLRP3/GSDMD pathway. *Int Immunopharmacol* **2022**, *113*, 109451, doi:10.1016/j.intimp.2022.109451.
159. Lutas, A.; Yellen, G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. *Trends Neurosci* **2013**, *36*, 32-40, doi:10.1016/j.tins.2012.11.005.
160. Miyauchi, T.; Uchida, Y.; Kadono, K.; Hirao, H.; Kawasoe, J.; Watanabe, T.; Ueda, S.; Okajima, H.; Terajima, H.; Uemoto, S. Up-regulation of FOXO1 and reduced inflammation by beta-hydroxybutyric acid are essential diet restriction benefits against liver injury. *Proc Natl Acad Sci U S A* **2019**, *116*, 13533-13542, doi:10.1073/pnas.1820282116.
161. Shippy, D.C.; Wilhelm, C.; Viharkumar, P.A.; Raife, T.J.; Ulland, T.K. beta-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology. *J Neuroinflammation* **2020**, *17*, 280, doi:10.1186/s12974-020-01948-5.
162. Youm, Y.H.; Nguyen, K.Y.; Grant, R.W.; Goldberg, E.L.; Bodogai, M.; Kim, D.; D'Agostino, D.; Planavsky, N.; Lupfer, C.; Kanneganti, T.D.; et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat Med* **2015**, *21*, 263-269, doi:10.1038/nm.3804.

163. Kim, D.Y.; Simeone, K.A.; Simeone, T.A.; Pandya, J.D.; Wilke, J.C.; Ahn, Y.; Geddes, J.W.; Sullivan, P.G.; Rho, J.M. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. *Ann Neurol* **2015**, *78*, 77-87, doi:10.1002/ana.24424.
164. Olson, C.A.; Vuong, H.E.; Yano, J.M.; Liang, Q.Y.; Nusbaum, D.J.; Hsiao, E.Y. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. *Cell* **2018**, *173*, 1728-1741 e1713, doi:10.1016/j.cell.2018.04.027.
165. Oronsky, B.; Takahashi, L.; Gordon, R.; Cabrales, P.; Caroën, S.; Reid, T. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. *Front Oncol* **2023**, *13*, 1204143, doi:10.3389/fonc.2023.1204143.
166. Chen, Y.; He, H.; Lin, B.; Chen, Y.; Deng, X.; Jiang, W.; Zhou, R. RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. *Cell Mol Immunol* **2021**, *18*, 1425-1436, doi:10.1038/s41423-021-00683-y.
167. Reid T, O.B., Caroën S, Cabrales P. The direct NLRP3 inhibitor and Phase 3 small molecule anticancer agent, RRx-001, protects aged triple transgenic Alzheimer's disease model mice from CNS degeneration and cognitive decline. *Alzheimer's Dement* **2022**, *18*, doi:doi: 10.1002/alz.061516.
168. Sun, Y.; Ma, J.; Li, D.; Li, P.; Zhou, X.; Li, Y.; He, Z.; Qin, L.; Liang, L.; Luo, X. Interleukin-10 inhibits interleukin-1 β production and inflammasome activation of microglia in epileptic seizures. *J Neuroinflammation* **2019**, *16*, 66, doi:10.1186/s12974-019-1452-1.
169. Li, Q.; Feng, H.; Wang, H.; Wang, Y.; Mou, W.; Xu, G.; Zhang, P.; Li, R.; Shi, W.; Wang, Z.; et al. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. *EMBO Rep* **2022**, *23*, e53499, doi:10.15252/embr.202153499.
170. Honda, H.; Nagai, Y.; Matsunaga, T.; Okamoto, N.; Watanabe, Y.; Tsuneyama, K.; Hayashi, H.; Fujii, I.; Ikutani, M.; Hirai, Y.; et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. *J Leukoc Biol* **2014**, *96*, 1087-1100, doi:10.1189/jlb.3A0114-005RR.
171. Zeng, J.; Chen, Y.; Ding, R.; Feng, L.; Fu, Z.; Yang, S.; Deng, X.; Xie, Z.; Zheng, S. Isoliquiritigenin alleviates early brain injury after experimental intracerebral hemorrhage via suppressing ROS- and/or NF-kappaB-mediated NLRP3 inflammasome activation by promoting Nrf2 antioxidant pathway. *J Neuroinflammation* **2017**, *14*, 119, doi:10.1186/s12974-017-0895-5.
172. Wang, K.; Lv, Q.; Miao, Y.M.; Qiao, S.M.; Dai, Y.; Wei, Z.F. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. *Biochem Pharmacol* **2018**, *155*, 494-509, doi:10.1016/j.bcp.2018.07.039.
173. Mohseni-Moghaddam, P.; Sadr, S.S.; Roghani, M.; Arabzadeh, S.; Khamse, S.; Zamani, E.; Hosseini, M.; Moradi, F. Huperzine A ameliorates cognitive dysfunction and neuroinflammation in kainic acid-induced epileptic rats by antioxidant activity and NLRP3/caspase-1 pathway inhibition. *Clin Exp Pharmacol Physiol* **2019**, *46*, 360-372, doi:10.1111/1440-1681.13064.
174. Samadianzakaria, A.; Abdolmaleki, Z.; Faedmaleki, F. The effect of valproic acid and furosemide on the regulation of the inflammasome complex (NLRP1 and NLRP3 mRNA) in the brain of epileptic animal model. *Brain Res Bull* **2022**, *191*, 20-29, doi:10.1016/j.brainresbull.2022.10.002.
175. Liu, R.; Wu, S.; Guo, C.; Hu, Z.; Peng, J.; Guo, K.; Zhang, X.; Li, J. Ibuprofen Exerts Antiepileptic and Neuroprotective Effects in the Rat Model of Pentylenetetrazol-Induced Epilepsy via the COX-2/NLRP3/IL-18 Pathway. *Neurochem Res* **2020**, *45*, 2516-2526, doi:10.1007/s11064-020-03109-9.
176. Aghaie, F.; Moradifar, F.; Hosseini, A. Rapamycin attenuates depression and anxiety-like behaviors through modulation of the NLRP3 pathway in pentylenetetrazole-kindled male Wistar rats. *Fundam Clin Pharmacol* **2021**, *35*, 1045-1054, doi:10.1111/fcp.12689.
177. Xia, S.; Yang, P.; Li, F.; Yu, Q.; Kuang, W.; Zhu, Y.; Lu, J.; Wu, H.; Li, L.; Huang, H. Chaihu-Longgu-Muli Decoction exerts an antiepileptic effect in rats by improving pyroptosis in hippocampal neurons. *J Ethnopharmacol* **2021**, *270*, 113794, doi:10.1016/j.jep.2021.113794.
178. He, H.; Jiang, H.; Chen, Y.; Ye, J.; Wang, A.; Wang, C.; Liu, Q.; Liang, G.; Deng, X.; Jiang, W.; et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. *Nat Commun* **2018**, *9*, 2550, doi:10.1038/s41467-018-04947-6.
179. Juliana, C.; Fernandes-Alnemri, T.; Wu, J.; Datta, P.; Solorzano, L.; Yu, J.W.; Meng, R.; Quong, A.A.; Latz, E.; Scott, C.P.; et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. *J Biol Chem* **2010**, *285*, 9792-9802, doi:10.1074/jbc.M109.082305.
180. Wu, L.; Chen, M.; Li, M.; Wang, Y.; Li, Y.; Zheng, L.; Ke, Z.; Liu, K.; Qiao, Y.; Shi, X. Oridonin alleviates kanamycin-related hearing loss by inhibiting NLRP3/caspase-1/gasdermin D-induced inflammasome activation and hair cell pyroptosis. *Mol Immunol* **2022**, *149*, 66-76, doi:10.1016/j.molimm.2022.06.006.
181. Agarwal, N.B.; Jain, S.; Nagpal, D.; Agarwal, N.K.; Mediratta, P.K.; Sharma, K.K. Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice. *Fundam Clin Pharmacol* **2013**, *27*, 169-172, doi:10.1111/j.1472-8206.2011.01002.x.
182. Bharal, N.; Sahaya, K.; Jain, S.; Mediratta, P.K.; Sharma, K.K. Curcumin has anticonvulsant activity on increasing current electroshock seizures in mice. *Phytother Res* **2008**, *22*, 1660-1664, doi:10.1002/ptr.2551.

183. Choudhary, K.M.; Mishra, A.; Poroikov, V.V.; Goel, R.K. Ameliorative effect of Curcumin on seizure severity, depression like behavior, learning and memory deficit in post-pentylenetetrazole-kindled mice. *Eur J Pharmacol* **2013**, *704*, 33-40, doi:10.1016/j.ejphar.2013.02.012.
184. Gupta, Y.K.; Briyal, S.; Sharma, M. Protective effect of curcumin against kainic acid induced seizures and oxidative stress in rats. *Indian J Physiol Pharmacol* **2009**, *53*, 39-46.
185. Hashemian, M.; Anissian, D.; Ghasemi-Kasman, M.; Akbari, A.; Khalili-Fomeshi, M.; Ghasemi, S.; Ahmadi, F.; Moghadamnia, A.A.; Ebrahimpour, A. Curcumin-loaded chitosan-alginate-STPP nanoparticles ameliorate memory deficits and reduce glial activation in pentylenetetrazol-induced kindling model of epilepsy. *Prog Neuropsychopharmacol Biol Psychiatry* **2017**, *79*, 462-471, doi:10.1016/j.pnpbp.2017.07.025.
186. Yin, H.; Guo, Q.; Li, X.; Tang, T.; Li, C.; Wang, H.; Sun, Y.; Feng, Q.; Ma, C.; Gao, C.; et al. Curcumin Suppresses IL-1 β Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome. *J Immunol* **2018**, *200*, 2835-2846, doi:10.4049/jimmunol.1701495.
187. Yang, Z.; Zhong, L.; Xian, R.; Yuan, B. MicroRNA-223 regulates inflammation and brain injury via feedback to NLRP3 inflammasome after intracerebral hemorrhage. *Mol Immunol* **2015**, *65*, 267-276, doi:10.1016/j.molimm.2014.12.018.
188. Haneklaus, M.; Gerlic, M.; Kurowska-Stolarska, M.; Rainey, A.A.; Pich, D.; McInnes, I.B.; Hammerschmidt, W.; O'Neill, L.A.; Masters, S.L. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1 β production. *J Immunol* **2012**, *189*, 3795-3799, doi:10.4049/jimmunol.1200312.
189. Qingfeng Meng, X.H., Hui Sun, Hao Wang, Zhenfeng Luan, Shoudong Wang. miR-223 regulates myocardial ischemia-reperfusion damage via targeting NLRP3 in vitro and in vivo. *Int J Clin Exp Med* **2018**, *11*.
190. Wang, R.; Li, Q.; He, Y.; Yang, Y.; Ma, Q.; Li, C. miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease. *Genes Cells* **2020**, *25*, 364-374, doi:10.1111/gtc.12764.
191. Chen, D.; Dixon, B.J.; Doycheva, D.M.; Li, B.; Zhang, Y.; Hu, Q.; He, Y.; Guo, Z.; Nowrangi, D.; Flores, J.; et al. IRE1 α inhibition decreased TXNIP/NLRP3 inflammasome activation through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats. *J Neuroinflammation* **2018**, *15*, 32, doi:10.1186/s12974-018-1077-9.
192. Gong, L.; Han, Y.; Chen, R.; Yang, P.; Zhang, C. LncRNA ZNF883-Mediated NLRP3 Inflammasome Activation and Epilepsy Development Involve USP47 Upregulation. *Mol Neurobiol* **2022**, *59*, 5207-5221, doi:10.1007/s12035-022-02902-7.
193. Zhang, A.; Lu, Y.; Yuan, L.; Zhang, P.; Zou, D.; Wei, F.; Chen, X. miR-29a-5p Alleviates Traumatic Brain Injury- (TBI-) Induced Permeability Disruption via Regulating NLRP3 Pathway. *Dis Markers* **2021**, *2021*, 9556513, doi:10.1155/2021/9556513.
194. Zamani, P.; Oskuee, R.K.; Atkin, S.L.; Navashenaq, J.G.; Sahebkar, A. MicroRNAs as important regulators of the NLRP3 inflammasome. *Prog Biophys Mol Biol* **2020**, *150*, 50-61, doi:10.1016/j.pbiomolbio.2019.05.004.
195. Kennedy, C.R.; Goya Grocin, A.; Kovacic, T.; Singh, R.; Ward, J.A.; Shenoy, A.R.; Tate, E.W. A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target. *ACS Chem Biol* **2021**, *16*, 982-990, doi:10.1021/acscmbio.1c00218.
196. Kadioglu, O.; Saeed, M.; Kuete, V.; Greten, H.J.; Efferth, T. Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses. *Front Pharmacol* **2018**, *9*, 355, doi:10.3389/fphar.2018.00355.
197. Agarwal, S.; Pethani, J.P.; Shah, H.A.; Vyas, V.; Sasane, S.; Bhavsar, H.; Bandyopadhyay, D.; Giri, P.; Viswanathan, K.; Jain, M.R.; et al. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor. *Bioorg Med Chem Lett* **2020**, *30*, 127571, doi:10.1016/j.bmcl.2020.127571.
198. Agarwal, S.; Sasane, S.; Shah, H.A.; Pethani, J.P.; Deshmukh, P.; Vyas, V.; Iyer, P.; Bhavsar, H.; Viswanathan, K.; Bandyopadhyay, D.; et al. Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors. *ACS Med Chem Lett* **2020**, *11*, 414-418, doi:10.1021/acsmchemlett.9b00433.
199. Smolak, P.; Nguyen, M.; Diamond, C.; Wescott, H.; Doedens, J.R.; Schooley, K.; Snouwaert, J.N.; Bock, M.G.; Harrison, D.; Watt, A.P.; et al. Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. *J Pharmacol Exp Ther* **2024**, *388*, 798-812, doi:10.1124/jpet.123.001941.
200. Yetisgin, A.A.; Cetinel, S.; Zuvin, M.; Kosar, A.; Kutlu, O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. *Molecules* **2020**, *25*, doi:10.3390/molecules25092193.
201. Mancuso, R.; Citterio, L.A.; Agostini, S.; Marventano, I.; La Rosa, F.; Re, F.; Seneci, P.; Saresella, M.; Clerici, M. Glibenclamide-Loaded Nanoparticles Reduce NLRP3 Inflammasome Activation and Modulate miR-223-3p/miR-7-1-5p Expression in THP-1 Cells. *Pharmaceuticals (Basel)* **2023**, *16*, doi:10.3390/ph16111590.
202. Nandi, D.; Debnath, M.; Forster, J., 3rd; Pandey, A.; Bharadwaj, H.; Patel, R.; Kulkarni, A. Nanoparticle-mediated co-delivery of inflammasome inhibitors provides protection against sepsis. *Nanoscale* **2024**, *16*, 4678-4690, doi:10.1039/d3nr05570a.

203. Tang, J.; Li, T.; Xiong, X.; Yang, Q.; Su, Z.; Zheng, M.; Chen, Q. Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-kappaB/NLRP3 pathways in inflammatory endothelial cells. *J Nanobiotechnology* **2023**, *21*, 460, doi:10.1186/s12951-023-02228-z.
204. Chen, X.; Zhou, Y.; Yu, J. Exosome-like Nanoparticles from Ginger Rhizomes Inhibited NLRP3 Inflammasome Activation. *Mol Pharm* **2019**, *16*, 2690-2699, doi:10.1021/acs.molpharmaceut.9b00246.
205. Liu, B.; Li, X.; Yu, H.; Shi, X.; Zhou, Y.; Alvarez, S.; Naldrett, M.J.; Kachman, S.D.; Ro, S.H.; Sun, X.; et al. Therapeutic potential of garlic chive-derived vesicle-like nanoparticles in NLRP3 inflammasome-mediated inflammatory diseases. *Theranostics* **2021**, *11*, 9311-9330, doi:10.7150/thno.60265.
206. Muhammad, W.; Zhu, J.; Zhai, Z.; Xie, J.; Zhou, J.; Feng, X.; Feng, B.; Pan, Q.; Li, S.; Venkatesan, R.; et al. ROS-responsive polymer nanoparticles with enhanced loading of dexamethasone effectively modulate the lung injury microenvironment. *Acta Biomater* **2022**, *148*, 258-270, doi:10.1016/j.actbio.2022.06.024.
207. Liu, X.; Lu, B.; Fu, J.; Zhu, X.; Song, E.; Song, Y. Amorphous silica nanoparticles induce inflammation via activation of NLRP3 inflammasome and HMGB1/TLR4/MYD88/NF-kb signaling pathway in HUVEC cells. *J Hazard Mater* **2021**, *404*, 124050, doi:10.1016/j.jhazmat.2020.124050.
208. Sharma, B.; McLeland, C.B.; Potter, T.M.; Stern, S.T.; Adiseshaiah, P.P. Assessing NLRP3 Inflammasome Activation by Nanoparticles. *Methods Mol Biol* **2018**, *1682*, 135-147, doi:10.1007/978-1-4939-7352-1_12.
209. Shirasuna, K.; Karasawa, T.; Takahashi, M. Exogenous nanoparticles and endogenous crystalline molecules as danger signals for the NLRP3 inflammasomes. *J Cell Physiol* **2019**, *234*, 5436-5450, doi:10.1002/jcp.27475.
210. Wang, X.; Lin, J.; Wang, Z.; Li, Z.; Wang, M. Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer. *Discov Oncol* **2023**, *14*, 93, doi:10.1007/s12672-023-00701-7.
211. Debnath, M.; Forster, J., 3rd; Ramesh, A.; Kulkarni, A. Protein Corona Formation on Lipid Nanoparticles Negatively Affects the NLRP3 Inflammasome Activation. *Bioconjug Chem* **2023**, *34*, 1766-1779, doi:10.1021/acs.bioconjchem.3c00329.
212. Rajendran, G.; Bhanu, D.; Aruchamy, B.; Ramani, P.; Pandurangan, N.; Bobba, K.N.; Oh, E.J.; Chung, H.Y.; Gangadaran, P.; Ahn, B.C. Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry. *Pharmaceuticals (Basel)* **2022**, *15*, doi:10.3390/ph15101250.
213. Thapa, P.; Upadhyay, S.P.; Suo, W.Z.; Singh, V.; Gurung, P.; Lee, E.S.; Sharma, R.; Sharma, M. Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease. *Bioorg Chem* **2021**, *108*, 104681, doi:10.1016/j.bioorg.2021.104681.
214. Thapa, P.; Upadhyay, S.P.; Singh, V.; Boinpelly, V.C.; Zhou, J.; Johnson, D.K.; Gurung, P.; Lee, E.S.; Sharma, R.; Sharma, M. Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors. *Eur J Med Chem Rep* **2023**, *7*, doi:10.1016/j.ejmcr.2022.100100.
215. Zhang, C.; Yue, H.; Sun, P.; Hua, L.; Liang, S.; Ou, Y.; Wu, D.; Wu, X.; Chen, H.; Hao, Y.; et al. Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. *Eur J Med Chem* **2021**, *219*, 113417, doi:10.1016/j.ejmech.2021.113417.
216. Jiang, W.; Li, M.; He, F.; Zhou, S.; Zhu, L. Targeting the NLRP3 inflammasome to attenuate spinal cord injury in mice. *J Neuroinflammation* **2017**, *14*, 207, doi:10.1186/s12974-017-0980-9.
217. Zhao, X.J.; Zhu, H.Y.; Wang, X.L.; Lu, X.W.; Pan, C.L.; Xu, L.; Liu, X.; Xu, N.; Zhang, Z.Y. Oridonin Ameliorates Traumatic Brain Injury-Induced Neurological Damage by Improving Mitochondrial Function and Antioxidant Capacity and Suppressing Neuroinflammation through the Nrf2 Pathway. *J Neurotrauma* **2022**, *39*, 530-543, doi:10.1089/neu.2021.0466.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.